MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122425||ORU^R01|Q199816389T198313506|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439413^101LA|4356952^URINALYSIS^L01N|||20101203122200|||||||20101203122200|^^|1001745^Test, Physician - p-Test Physician||||10-337-300046||20101203122421||LA|F||1^^^20101203122100^^RT~^^^^^RT|OBX|1|ST|4669021^COLOR^L01N||Yellow||||||F|||20101203122419OBX|2|ST|4668985^APPEARANCE^L01N||Clear||||||F|||20101203122419OBX|3|ST|4673824^SPECIFIC GRAVITY^L01N||1.015||<=1.030||||F|||20101203122419OBX|4|ST|4673257^PH^L01N||7.0||5.0-8.5||||F|||20101203122419OBX|5|ST|4669045^LEUKOCYTE^L01N||Moderate||Negative|A|||F|||20101203122419OBX|6|ST|4669051^NITRITE^L01N||Positive||Negative|A|||F|||20101203122419OBX|7|ST|3316682^PROTEIN^L01N||Negative|g/L|Negative||||F|||20101203122419OBX|8|ST|4673845^GLUCOSE^L01N||Negative|mmol/L|Negative||||F|||20101203122419OBX|9|ST|4669276^KETONES^L01N||Negative||Negative||||F|||20101203122419OBX|10|ST|4669003^BLOOD^L01N||Small||Negative|A|||F|||20101203122419
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122426||ORU^R01|Q199816391T198313508|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439429^101LA|2921834^URINE MICROSCOPIC^L01N|||20101203122200|||||||20101203122200|^^|1001745^Test, Physician - p-Test Physician||||10-337-300046||20101203122422||LA|F||1^^^20101203122200^^RT~^^^^^RT|OBX|1|ST|4669219^WBC^L01N||6-10|/HPF|0-5|A|||F|||20101203122419OBX|2|ST|4669186^RBC^L01N||6-10|/HPF|0-5|A|||F|||20101203122419OBX|3|ST|4676194^EPITHELIAL CELLS^L01N||Few|/HPF|||||F|||20101203122419OBX|4|ST|4668988^URINE BACTERIA^L01N||Few|/HPF|||||F|||20101203122419OBX|5|ST|4668928^HYALINE CASTS^L01N||0-4|/LPF|||||F|||20101203122419
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122622||ORU^R01|Q199816397T198313514|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439443^101LA|4356952^URINALYSIS^L01N|||20101203122500|||||||20101203122500|^^|1001745^Test, Physician - p-Test Physician||||10-337-300047||20101203122619||LA|F||1^^^20101203122500^^RT~^^^^^RT|OBX|1|TX|6810081^Urinalysis Comment^L01N||See Note||||||F|||20101203122617NTE|1|C|Microscopic examination not performed due to negative Blood, Nitrite,NTE|2|C|Leukocyte Esterase and Protein.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122634||ORU^R01|Q199816399T198313516|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439443^101LA|4356952^URINALYSIS^L01N|||20101203122500|||||||20101203122500|^^|1001745^Test, Physician - p-Test Physician||||10-337-300047||20101203122631||LA|F||1^^^20101203122500^^RT~^^^^^RT|OBX|1|ST|4669021^COLOR^L01N||Yellow||||||F|||20101203122628OBX|2|ST|4668985^APPEARANCE^L01N||Clear||||||F|||20101203122628OBX|3|ST|4673824^SPECIFIC GRAVITY^L01N||1.010||<=1.030||||F|||20101203122628OBX|4|ST|4673257^PH^L01N||6.0||5.0-8.5||||F|||20101203122628OBX|5|ST|4669045^LEUKOCYTE^L01N||Negative||Negative||||F|||20101203122628OBX|6|ST|4669051^NITRITE^L01N||Negative||Negative||||F|||20101203122628OBX|7|ST|3316682^PROTEIN^L01N||Negative|g/L|Negative||||F|||20101203122628OBX|8|ST|4673845^GLUCOSE^L01N||Negative|mmol/L|Negative||||F|||20101203122628OBX|9|ST|4669276^KETONES^L01N||Negative||Negative||||F|||20101203122628OBX|10|ST|4669003^BLOOD^L01N||Negative||Negative||||F|||20101203122628OBX|11|TX|6810081^Urinalysis Comment^L01N||See Note||||||F|||20101203122617NTE|1|C|Microscopic examination not performed due to negative Blood, Nitrite,NTE|2|C|Leukocyte Esterase and Protein.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122801||ORU^R01|Q199816401T198313518|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439370^101LA|2921852^VITAMIN D (25-HYDROXY)^L01N|||20101203121800|||||||20101203121900|^^|1001745^Test, Physician - p-Test Physician||||10-337-300042||20101203122758||LA|F||1^^^20101203121800^^RT~^^^^^RT|OBX|1|ST|4674013^VITAMIN D (25-HYDROXY)^L01N||<10.1|nmol/L|80.0-200.0|L|||F|||20101203122756NTE|1|C|Specimen slightly hemolyzed.NTE|2|I|Result Interpretation as Follows:NTE|3|I|Severe Deficiency               <25.0         nmol/LNTE|4|I|Moderate To Mild Deficiency    25.0 - 80.0   nmol/LNTE|5|I|Optimum Levels                  80.0 - 200.0  nmol/LNTE|6|I|Toxicity Possible               >250.0       nmol/L
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203122846||ORU^R01|Q199816407T198313524|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439455^101LA|2921495^D-DIMER (DVT/PE)^L01N|||20101203122800|||||||20101203122800|^^|1001745^Test, Physician - p-Test Physician||||10-337-300048||20101203122844||LA|F||1^^^20101203122800^^RT~^^^^^RT|OBX|1|NM|4669105^D-DIMER^L01N||0.55|mg/L FEU|<=0.50|H|||F|||20101203122841NTE|1|I|A D-Dimer level less than 0.51 mg/L FEU may be used with a standardizedNTE|2|I|clinical assessment and/or imaging studies to help exclude venousNTE|3|I|thromboembolism.  Values above the cut-off are not diagnostically used for VTENTE|4|I|assessment.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101203123040||ORU^R01|Q199816411T198313528|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439373^101LA|2921802^DRUG SCREEN URINE - TOXICOLOGY^L01N|||20101203121800|||||||20101203122000|^^|1001745^Test, Physician - p-Test Physician||||10-337-300043||20101203123037||LA|F||1^^^20101203121800^^RT~^^^20101203121800^^RT|OBX|1|ST|4677619^URINE TOXICOLOGY REPORT^L01N||prelimiary findings show the presence of cannabiniods||||||F|||20101203123034NTE|1|I|Results are intended to be used for medical (i.e. treatment) purposes.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209094914||ORU^R01|Q199820946T198318041|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439468^101LA|12104818^DRUG SCREEN URINE - FINAL^L01N|||20101203121800|||||||20101203122000|^^|1001745^Test, Physician - p-Test Physician||||10-337-300043||20101209094921||LA|F||1^^^20101203121800^^RT~^^^^^RT|OBX|1|ST|12152702^Drug Screen Urine Final^L01N||The presence of Cannabiniods have been confirmed by GC-MS testing.||||||F|||20101209094915
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209104801||ORU^R01|Q199821192T198318291|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439373^101LA|2921802^DRUG SCREEN URINE - TOXICOLOGY^L01N|||20101203121800|||||||20101203122000|^^|1001745^Test, Physician - p-Test Physician||||10-337-300043||20101203123037||LA|F||1^^^20101203121800^^RT~^^^20101203121800^^RT|OBX|1|ST|4677619^URINE TOXICOLOGY REPORT^L01N||prelimiary findings show the presence of cannabiniods  *************************************** ERROR - Disregard above report ***************************************||||||C|||20101209104802NTE|1|I|Results are intended to be used for medical (i.e. treatment) purposes.NTE|2|I|Results are intended to be used for medical (i.e. treatment) purposes.NTE|3||Corrected from   [NA] on 12/03/2010 12:30:34 MDT by MLTGL.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209104801||ORU^R01|Q199821194T198318293|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439468^101LA|12104818^DRUG SCREEN URINE - FINAL^L01N|||20101203121800|||||||20101203122000|^^|1001745^Test, Physician - p-Test Physician||||10-337-300043||20101209094921||LA|F||1^^^20101203121800^^RT~^^^^^RT|OBX|1|ST|12152702^Drug Screen Urine Final^L01N||The presence of Cannabiniods have been confirmed by GC-MS testing||||||C|||20101209104802OBX|2|ST|12152702^Drug Screen Urine Final^L01N||||||||C|||20101209104802OBX|3|ST|12152702^Drug Screen Urine Final^L01N||**********************************************||||||C|||20101209104802OBX|4|ST|12152702^Drug Screen Urine Final^L01N||ERROR- Please disregard above report||||||C|||20101209104802OBX|5|ST|12152702^Drug Screen Urine Final^L01N||**********************************************||||||C|||20101209104802OBX|6|ST|12152702^Drug Screen Urine Final^L01N||GC-MS testing has confirmed the presence of Barbiturate metabolites||||||C|||20101209104802
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209121440||ORU^R01|Q199821404T198318506|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448776^101LA|2921521^FOLLICLE STIMULATING HORMONE^L01N|||20101209121300|||||||20101209121300|^^|1001745^Test, Physician - p-Test Physician||||10-343-300087||20101209121448||LA|F||1^^^20101209121300^^RT~^^^^^RT|OBX|1|NM|4673182^FSH^L01N||16|IU/L|||||F|||20101209121442
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209121441||ORU^R01|Q199821406T198318508|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448776^101LA|2921521^FOLLICLE STIMULATING HORMONE^L01N|||20101209121300|||||||20101209121300|^^|1001745^Test, Physician - p-Test Physician||||10-343-300087||20101209121448||LA|F||1^^^20101209121300^^RT~^^^^^RT|OBX|1|NM|4673182^FSH^L01N||16|IU/L|||||F|||20101209121442OBX|2|TX|6810151^FSH COMMENT^L01N||See Note||||||F|||20101209121443NTE|1|C|Female Reference Ranges:NTE|2|C|Follicular Phase:     2 - 10 IU/LNTE|3|C|Mid-Cycle Peak:     3 - 33 IU/LNTE|4|C|Luteal Phase:          1 - 9 IU/LNTE|5|C|Post-Menopausal:   23 - 116 IU/LNTE|6|C|                                           .
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209121937||ORU^R01|Q199821416T198318516|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448784^101LA|2921686^PHENYTOIN^L01N|||20101209121300|||||||20101209121800|^^|1001745^Test, Physician - p-Test Physician||||10-343-300088||20101209121944||LA|F||1^^^20101209121300^^RT~^^^^^RT|OBX|1|NM|4673215^PHENYTOIN^L01N||76|umol/L|40-80||||F|||20101209121938OBX|2|ST|4672225^DATE LAST PHENYTOIN^L01N||20101209||||||F|||20101209121938OBX|3|ST|4672915^TIME DOSE PHENYTOIN^L01N||0800||||||F|||20101209121938
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209122130||ORU^R01|Q199821425T198318525|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448796^101LA|2921259^POTASSIUM^L01N|||20101209121300|||||||20101209122100|^^|1001745^Test, Physician - p-Test Physician||||10-343-300089||20101209122138||LA|F||1^^^20101209121300^^RT~^^^^^RT|OBX|1|NM|4673635^POTASSIUM^L01N||8.7|mmol/L|3.3-5.1|C|||F|||20101209122131
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209130651||ORU^R01|Q199821475T198318570|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448827^101LA|8232642^HEMOGLOBIN AND HEMATOCRIT^L01N|||20101209130500|||||||20101209130500|^^|1001745^Test, Physician - p-Test Physician||||10-343-300090||20101209130658||LA|F||1^^^20101209130500^^RT~^^^^^RT|OBX|1|NM|12152330^HEMOGLOBIN..^L01N||165|g/L|120-160|H|||F|||20101209130652OBX|2|NM|12332593^HEMATOCRIT..^L01N||0.42|L/L|0.36-0.48||||F|||20101209130652
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209131021||ORU^R01|Q199821483T198318577|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448835^101LA|4356874^IMMUNOGLOBULIN G^L01N|||20101209130500|||||||20101209130800|^^|1001745^Test, Physician - p-Test Physician||||10-343-300091||20101209131028||LA|F||1^^^20101209130500^^RT~^^^^^RT|OBX|1|ST|4674253^IMMUNOGLOBULIN G^L01N||<0.52|g/L|6.80-18.00|L|||F|||20101209131022
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209134852||ORU^R01|Q199821620T198318714|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448887^101LA|9493207^COMPLETE BLOOD COUNT^L01N|||20101209133700|||||||20101209133700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300092||20101209134857||LA|F||1^^^20101209133700^^RT~^^^20101209133700^^RT|OBX|1|NM|4672972^HEMOGLOBIN^L01N||141|g/L|120 - 160||||F|||20101209134851OBX|2|NM|4673716^HEMATOCRIT^L01N||0.41|L/L|0.36 - 0.48||||F|||20101209134851OBX|3|NM|4673467^RBC^L01N||4.0|10E12/L|4.0 - 5.6||||F|||20101209134851OBX|4|NM|4673050^MCV^L01N||82|fL|82 - 100||||F|||20101209134851OBX|5|NM|4673047^MCHC^L01N||332|g/L|320 - 360||||F|||20101209134851OBX|6|NM|4673476^RDW^L01N||18.0|%|11.0 - 16.0|H|||F|||20101209134851OBX|7|NM|4673236^PLATELET COUNT^L01N||42|10E9/L|150 - 400|L|||F|||20101209134851OBX|8|NM|4673800^WBC^L01N||10.0|10E9/L|4.0 - 11.0||||F|||20101209134851
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209134853||ORU^R01|Q199821622T198318716|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448887^101LA|9493207^COMPLETE BLOOD COUNT^L01N|||20101209133700|||||||20101209133700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300092||20101209134858||LA|F||1^^^20101209133700^^RT~^^^20101209133700^^RT|OBX|1|NM|4672972^HEMOGLOBIN^L01N||141|g/L|120 - 160||||F|||20101209134851OBX|2|NM|4673716^HEMATOCRIT^L01N||0.41|L/L|0.36 - 0.48||||F|||20101209134851OBX|3|NM|4673467^RBC^L01N||4.0|10E12/L|4.0 - 5.6||||F|||20101209134851OBX|4|NM|4673050^MCV^L01N||82|fL|82 - 100||||F|||20101209134851OBX|5|NM|4673047^MCHC^L01N||332|g/L|320 - 360||||F|||20101209134851OBX|6|NM|4673476^RDW^L01N||18.0|%|11.0 - 16.0|H|||F|||20101209134851OBX|7|NM|4673236^PLATELET COUNT^L01N||42|10E9/L|150 - 400|L|||F|||20101209134851OBX|8|NM|4673800^WBC^L01N||10.0|10E9/L|4.0 - 11.0||||F|||20101209134851OBX|9|NM|4674889^NEUTROPHILS^L01N||6.0|10E9/L|2.0 - 9.0||||F|||20101209134851OBX|10|NM|4673014^LYMPHOCYTES^L01N||3.0|10E9/L|0.5 - 3.3||||F|||20101209134851OBX|11|NM|4673074^MONOCYTES^L01N||1.0|10E9/L|0.0 - 1.0||||F|||20101209134851OBX|12|NM|4674892^EOSINOPHILS^L01N||0.0|10E9/L|0.0 - 0.7||||F|||20101209134851OBX|13|NM|4673350^BASOPHILS^L01N||0.0|10E9/L|0.0 - 0.2||||F|||20101209134851
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209140004||ORU^R01|Q199821652T198318746|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448887^101LA|9493207^COMPLETE BLOOD COUNT^L01N|||20101209133700|||||||20101209133700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300092||20101209134857||LA|F||1^^^20101209133700^^RT~^^^20101209133700^^RT|OBX|1|NM|4672972^HEMOGLOBIN^L01N||141|g/L|120 - 160||||F|||20101209134851OBX|2|NM|4673716^HEMATOCRIT^L01N||0.41|L/L|0.36 - 0.48||||F|||20101209134851OBX|3|NM|4673467^RBC^L01N||3.9|10E12/L|4.0 - 5.6|L|||C|||20101209140005NTE|1||Corrected from 4.0 10E12/L on 12/09/2010 13:48:51 MDT by MLTRRL.OBX|4|NM|4673050^MCV^L01N||82|fL|82 - 100||||F|||20101209134851OBX|5|NM|4673047^MCHC^L01N||332|g/L|320 - 360||||F|||20101209134851OBX|6|NM|4673476^RDW^L01N||18.0|%|11.0 - 16.0|H|||F|||20101209134851OBX|7|TX|4673236^PLATELET COUNT^L01N||Clumped|10E9/L|150 - 400||||C|||20101209140005NTE|1|C|Platelets appear decreased on smear. Unable to make an accurate assessment of the platelets due to clumping. Suggest recollection of the patient's CBC using EDTA, sodium citrate and sodium heparin anticoagulant tubes.NTE|2||Corrected from 42 10E9/L [LOW] on 12/09/2010 13:48:51 MDT by MLTRRL.OBX|8|NM|4673800^WBC^L01N||10.0|10E9/L|4.0 - 11.0||||F|||20101209134851OBX|9|NM|4674889^NEUTROPHILS^L01N||6.0|10E9/L|2.0 - 9.0||||F|||20101209134851OBX|10|NM|4673014^LYMPHOCYTES^L01N||3.0|10E9/L|0.5 - 3.3||||F|||20101209134851OBX|11|NM|4673074^MONOCYTES^L01N||1.0|10E9/L|0.0 - 1.0||||F|||20101209134851OBX|12|NM|4674892^EOSINOPHILS^L01N||0.0|10E9/L|0.0 - 0.7||||F|||20101209134851OBX|13|NM|4673350^BASOPHILS^L01N||0.0|10E9/L|0.0 - 0.2||||F|||20101209134851
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209144631||ORU^R01|Q199821750T198318838|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176448997^101LA|4382056^DIFFERENTIAL^L01N|||20101209133700|||||||20101209133700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300092||20101209144638||LA|F||1^^^20101209133700^^RT~^^^^^RT|OBX|1|ST|4670050^SMUDGE CELLS^L01N||Present||||||F|||20101209144632OBX|2|ST|4670053^ABNORMAL LYMPHOCYTES^L01N||Present||||||F|||20101209144632OBX|3|ST|4670056^AUER RODS^L01N||Present||||||F|||20101209144632
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209172228||ORU^R01|Q199821920T198318997|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449247^101BA|4389639^ABO RH TYPE^L01N|||20101209171000|||||||20101209171000|^^|1001745^Test, Physician - p-Test Physician||||10-343-300110||20101209172235||BA|F||1^^^20101209171000^^RT~^^^^^RT|NTE|1|C|Order level comment added to Type.OBX|1|TX|4600112^ABO RH TYPE^L01N||B Positive||||||F|||20101209172228
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209172420||ORU^R01|Q199821924T198319001|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449250^101BA|4655785^ANTIBODY SCREEN^L01N|||20101209171000|||||||20101209171000|^^|1001745^Test, Physician - p-Test Physician||||10-343-300110||20101209172427||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600115^ANTIBODY SCREEN^L01N||Positive|||A|||F|||20101209172425NTE|1|C|2010-12-09 17:24  JMARYKANTE|2|C|Result level comment added to Antibody Screen.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209172547||ORU^R01|Q199821930T198319007|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449294^101BA|4389615^ANTIBODY IDENTIFICATION^L01N|||20101209171000|||||||20101209171000|^^|1001745^Test, Physician - p-Test Physician||||10-343-300110||20101209172429||BA|F||1^^^20101209171000^^RT~^^^^^RT|OBX|1|TX|4600143^ANTIBODY IDENTIFICATION^L01N||Anti-K||||||F|||20101209172551OBX|2|TX|4600143^ANTIBODY IDENTIFICATION^L01N||Anti-Fya||||||F|||20101209172551
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209173225||ORU^R01|Q199821960T198319035|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449303^101BA|4655769^TYPE AND SCREEN^L01N|||20101209171000|||||||20101209172700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300111||20101209173232||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600112^ABO RH TYPE^L01N||B Positive||||||F|||20101209173231
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209173225||ORU^R01|Q199821962T198319037|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449303^101BA|4655769^TYPE AND SCREEN^L01N|||20101209171000|||||||20101209172700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300111||20101209173232||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600112^ABO RH TYPE^L01N||B Positive||||||F|||20101209173231OBX|2|TX|4600115^ANTIBODY SCREEN^L01N||Negative||||||F|||20101209173231OBX|3|ST|5086280^Cancellation Date^L01N||20101215||||||F|||20101209173231
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209173226||ORU^R01|Q199821964T198319039|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449303^101BA|4655769^TYPE AND SCREEN^L01N|||20101209171000|||||||20101209172700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300111||20101209173232||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600112^ABO RH TYPE^L01N||B Positive||||||F|||20101209173231OBX|2|TX|4600115^ANTIBODY SCREEN^L01N||Negative||||||F|||20101209173231OBX|3|TX|5802574^RTSIS Number^L01N||TGG 0987||||||F|||20101209173231OBX|4|ST|5086280^Cancellation Date^L01N||20101215||||||F|||20101209173231
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209173226||ORU^R01|Q199821966T198319041|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449303^101BA|4655769^TYPE AND SCREEN^L01N|||20101209171000|||||||20101209172700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300111||20101209173232||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600112^ABO RH TYPE^L01N||B Positive||||||F|||20101209173231OBX|2|TX|4600115^ANTIBODY SCREEN^L01N||Negative||||||F|||20101209173231OBX|3|TX|5802574^RTSIS Number^L01N||TGG 0987||||||F|||20101209173231OBX|4|ST|5086280^Cancellation Date^L01N||20101215||||||F|||20101209173231
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209173228||ORU^R01|Q199821972T198319047|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||990176449303^101BA|4655769^TYPE AND SCREEN^L01N|||20101209171000|||||||20101209172700|^^|1001745^Test, Physician - p-Test Physician||||10-343-300111||20101209173236||BA|F||1^^0^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|ST|8030877^COMMENT^L01N||Antibody Screen Comment: Red Cells available if required.||||||F|||20101209173236
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101209174924||ORU^R01|Q199821974T198319049|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176449250^101BA|4655785^ANTIBODY SCREEN^L01N|||20101209171000|||||||20101209171000|^^|1001745^Test, Physician - p-Test Physician||||10-343-300110||20101209172427||BA|F||1^^^20101209171000^^RT~^^^20101209171000^^RT|OBX|1|TX|4600115^ANTIBODY SCREEN^L01N||Negative||||||C|||20101209174931NTE|1|C|2010-12-09 17:24  JMARYKANTE|2|C|Result level comment added to Antibody Screen.NTE|3||Corrected from Positive  [ABN] on 12/09/2010 17:24:25 MDT by JMARYKA.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210074718||ORU^R01|Q199822400T198319473|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176450368^101LA|12943991^OCCULT BLOOD X3^L01N|||20101210074200|||||||20101210074500|^^|1001745^Test, Physician - p-Test Physician||||10-344-300006||20101210074723||LA|F||1^^^20101210074200^^RT~^^^20101210074200^^RT|OBX|1|TX|4670188^OCCULT BLOOD 1^L01N||Negative||Negative||||F|||20101210074717NTE|1|I|The Alberta Colorectal Screening Program recommends that the Fecal Occult Blood Test (FOBT) should primarily be used for annual colorectal cancer screening in asymptomatic 50-74 y individuals without risk factors for colorectal cancer. The use of the FOBT for the investigation of disease is of limited value. A Positive FOBT should be investigated by complete evaluation of the colon, preferably by colonoscopy. Repeating the FOBT is not recommended.OBX|2|ST|4672069^COLLECTION DATE^L01N||07-DEC-2010||||||F|||20101210074717OBX|3|TX|4669876^OCCULT BLOOD 2^L01N||Negative||Negative||||F|||20101210074717OBX|4|ST|4672027^COLLECTION DATE^L01N||08-DEC-2010||||||F|||20101210074717
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210074718||ORU^R01|Q199822402T198319476|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176450368^101LA|12943991^OCCULT BLOOD X3^L01N|||20101210074200|||||||20101210074600|^^|1001745^Test, Physician - p-Test Physician||||10-344-300006||20101210074723||LA|F||1^^^20101210074200^^RT~^^^20101210074200^^RT|OBX|1|TX|4670188^OCCULT BLOOD 1^L01N||Negative||Negative||||F|||20101210074717NTE|1|I|The Alberta Colorectal Screening Program recommends that the Fecal Occult Blood Test (FOBT) should primarily be used for annual colorectal cancer screening in asymptomatic 50-74 y individuals without risk factors for colorectal cancer. The use of the FOBT for the investigation of disease is of limited value. A Positive FOBT should be investigated by complete evaluation of the colon, preferably by colonoscopy. Repeating the FOBT is not recommended.OBX|2|ST|4672069^COLLECTION DATE^L01N||07-DEC-2010||||||F|||20101210074717OBX|3|TX|4669876^OCCULT BLOOD 2^L01N||Negative||Negative||||F|||20101210074717OBX|4|ST|4672027^COLLECTION DATE^L01N||08-DEC-2010||||||F|||20101210074717
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210074719||ORU^R01|Q199822404T198319479|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176450368^101LA|12943991^OCCULT BLOOD X3^L01N|||20101210074200|||||||20101210074600|^^|1001745^Test, Physician - p-Test Physician||||10-344-300006||20101210074724||LA|F||1^^^20101210074200^^RT~^^^20101210074200^^RT|OBX|1|TX|4670188^OCCULT BLOOD 1^L01N||Negative||Negative||||F|||20101210074717NTE|1|I|The Alberta Colorectal Screening Program recommends that the Fecal Occult Blood Test (FOBT) should primarily be used for annual colorectal cancer screening in asymptomatic 50-74 y individuals without risk factors for colorectal cancer. The use of the FOBT for the investigation of disease is of limited value. A Positive FOBT should be investigated by complete evaluation of the colon, preferably by colonoscopy. Repeating the FOBT is not recommended.OBX|2|ST|4672069^COLLECTION DATE^L01N||07-DEC-2010||||||F|||20101210074717OBX|3|TX|4669876^OCCULT BLOOD 2^L01N||Negative||Negative||||F|||20101210074717OBX|4|ST|4672027^COLLECTION DATE^L01N||08-DEC-2010||||||F|||20101210074717OBX|5|TX|4670191^OCCULT BLOOD 3^L01N||Positive||Negative|A|||F|||20101210074717OBX|6|ST|4672072^COLLECTION DATE^L01N||09-DEC-2010||||||F|||20101210074717
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210075154||ORU^R01|Q199822411T198319487|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176450392^101LA|2921210^GLUCOSE FASTING^L01N|||20101210074200|||||||20101210075000|^^|1001745^Test, Physician - p-Test Physician||||10-344-300007||20101210075201||LA|F||1^^^20101210074200^^RT~^^^^^RT|OBX|1|NM|4673692^GLUCOSE, FASTING^L01N||5.9|mmol/L|3.9-6.1||||F|||20101210075155OBX|2|ST|13202828^Hours Fasting^L01N||11 hours||||||F|||20101210075155
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210140837||ORU^R01|Q199822847T198319920|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450798^101MA|4356713^THROAT BETA STREP TEST^L01N|||20101210140000|||||||20101210140400|SWAB^^|1001745^Test, Physician - p-Test Physician||||TH-10-3000007||20101210140834||MA|F||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384243^THROAT BETA STREP TEST^L01N||*****Microbiology E.N.T/EYE*****||||||F|||20101210140834OBX|2|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|3|TX|4384243^THROAT BETA STREP TEST^L01N||                     TEST: Throat Beta Strep Test||||||F|||20101210140834OBX|4|TX|4384243^THROAT BETA STREP TEST^L01N||            SPECIMEN TYPE: Swab                     COLLECTED: 12/10/2010 14:00 MST||||||F|||20101210140834OBX|5|TX|4384243^THROAT BETA STREP TEST^L01N||          SPECIMEN SOURCE: Throat                    RECEIVED: 12/10/2010 14:05 MST||||||F|||20101210140834OBX|6|TX|4384243^THROAT BETA STREP TEST^L01N||                                                    ACCESSION: TH-10-3000007||||||F|||20101210140834OBX|7|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|8|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|9|TX|4384243^THROAT BETA STREP TEST^L01N||     FINAL REPORT                                    Verified:12/10/2010 14:08 MST||||||F|||20101210140834OBX|10|TX|4384243^THROAT BETA STREP TEST^L01N||     Test for Group A Streptococcus: Negative||||||F|||20101210140834OBX|11|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|12|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|13|TX|4384243^THROAT BETA STREP TEST^L01N||||||||F|||20101210140834OBX|14|TX|4384243^THROAT BETA STREP TEST^L01N||     __________________________________________________________||||||F|||20101210140834
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141101||ORU^R01|Q199822850T198319923|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450792^101MA|2922080^WOUND BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140200|Superficial Wound Swab^^right hand|1001745^Test, Physician - p-Test Physician||||WN-10-3000020||20101210141056||MA|P||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384298^WOUND BACTERIAL CULTURE^L01N||*****Microbiology Wound/Abscess*****||||||P|||20101210141056OBX|2|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|3|TX|4384298^WOUND BACTERIAL CULTURE^L01N||                     TEST: Wound Culture||||||P|||20101210141056OBX|4|TX|4384298^WOUND BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Superficial Wound Swab   COLLECTED: 12/10/2010 14:00 MST||||||P|||20101210141056OBX|5|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Finger                    RECEIVED: 12/10/2010 14:05 MST||||||P|||20101210141056OBX|6|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: right hand               ACCESSION: WN-10-3000020||||||P|||20101210141056OBX|7|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|8|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|9|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|10|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     GRAM STAIN REPORT                               Verified:12/10/2010 14:10 MST||||||P|||20101210141056OBX|11|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No neutrophils seen||||||P|||20101210141056OBX|12|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No epithelial cells seen||||||P|||20101210141056OBX|13|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No organisms seen||||||P|||20101210141056OBX|14|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|15|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|16|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     Additional info / info provided on requisition:||||||P|||20101210141056OBX|17|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     D1||||||P|||20101210141056OBX|18|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|19|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|20|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|21|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141056OBX|22|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     __________________________________________________________||||||P|||20101210141056
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141124||ORU^R01|Q199822853T198319926|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450792^101MA|2922080^WOUND BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140200|Superficial Wound Swab^^right hand|1001745^Test, Physician - p-Test Physician||||WN-10-3000020||20101210141121||MA|P||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384298^WOUND BACTERIAL CULTURE^L01N||*****Microbiology Wound/Abscess*****||||||P|||20101210141121OBX|2|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|3|TX|4384298^WOUND BACTERIAL CULTURE^L01N||                     TEST: Wound Culture||||||P|||20101210141121OBX|4|TX|4384298^WOUND BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Superficial Wound Swab   COLLECTED: 12/10/2010 14:00 MST||||||P|||20101210141121OBX|5|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Finger                    RECEIVED: 12/10/2010 14:05 MST||||||P|||20101210141121OBX|6|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: right hand               ACCESSION: WN-10-3000020||||||P|||20101210141121OBX|7|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|8|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|9|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|10|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     GRAM STAIN REPORT                               Verified:12/10/2010 14:10 MST||||||P|||20101210141121OBX|11|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No neutrophils seen||||||P|||20101210141121OBX|12|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No epithelial cells seen||||||P|||20101210141121OBX|13|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No organisms seen||||||P|||20101210141121OBX|14|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|15|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|16|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     PRELIMINARY REPORT                              Verified:12/10/2010 14:11 MST||||||P|||20101210141121OBX|17|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No growth||||||P|||20101210141121OBX|18|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|19|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|20|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     Additional info / info provided on requisition:||||||P|||20101210141121OBX|21|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     D1||||||P|||20101210141121OBX|22|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|23|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|24|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|25|TX|4384298^WOUND BACTERIAL CULTURE^L01N||||||||P|||20101210141121OBX|26|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     __________________________________________________________||||||P|||20101210141121
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141424||ORU^R01|Q199822860T198319933|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450795^101MA|2922077^URINE BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140400|URINE^^R/O YEAST|1001745^Test, Physician - p-Test Physician||||UR-10-3000032||20101210141416||MA|P||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384297^URINE BACTERIAL CULTURE^L01N||*****Microbiology Urine*****||||||P|||20101210141416OBX|2|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|3|TX|4384297^URINE BACTERIAL CULTURE^L01N||                     TEST: Urine Culture||||||P|||20101210141416OBX|4|TX|4384297^URINE BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Urine                    COLLECTED: 12/10/2010 14:00 MST||||||P|||20101210141416OBX|5|TX|4384297^URINE BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Post Pros. Massage Urine  RECEIVED: 12/10/2010 14:05 MST||||||P|||20101210141416OBX|6|TX|4384297^URINE BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: R/O YEAST                ACCESSION: UR-10-3000032||||||P|||20101210141416OBX|7|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|8|TX|4384297^URINE BACTERIAL CULTURE^L01N||     SUSCEPTIBILITY RESULTS ***||||||P|||20101210141416OBX|9|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Escherichia||||||P|||20101210141416OBX|10|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             coli||||||P|||20101210141416OBX|11|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|12|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp||||||P|||20101210141416OBX|13|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________||||||P|||20101210141416OBX|14|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ampicillin              S||||||P|||20101210141416OBX|15|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalothin(1)          S||||||P|||20101210141416OBX|16|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefazolin(1)            S||||||P|||20101210141416OBX|17|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefepime(1)             R||||||P|||20101210141416OBX|18|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ceftriaxone(1)          R||||||P|||20101210141416OBX|19|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Gentamicin              S||||||P|||20101210141416OBX|20|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S||||||P|||20101210141416OBX|21|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Norfloxacin             S||||||P|||20101210141416OBX|22|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S||||||P|||20101210141416OBX|23|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|24|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|25|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|26|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|27|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|28|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|29|TX|4384297^URINE BACTERIAL CULTURE^L01N||     *** SUSCEPTIBILITY FOOTNOTES||||||P|||20101210141416OBX|30|TX|4384297^URINE BACTERIAL CULTURE^L01N||     (1)||||||P|||20101210141416OBX|31|TX|4384297^URINE BACTERIAL CULTURE^L01N||     This organism has been shown to produce an Extended Spectrum Beta||||||P|||20101210141416OBX|32|TX|4384297^URINE BACTERIAL CULTURE^L01N||     lactamase (ESBL) and should be considered resistant to all||||||P|||20101210141416OBX|33|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalosporins.||||||P|||20101210141416OBX|34|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|35|TX|4384297^URINE BACTERIAL CULTURE^L01N||||||||P|||20101210141416OBX|36|TX|4384297^URINE BACTERIAL CULTURE^L01N||     __________________________________________________________||||||P|||20101210141416
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141648||ORU^R01|Q199822868T198319941|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450795^101MA|2922077^URINE BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140400|URINE^^R/O YEAST|1001745^Test, Physician - p-Test Physician||||UR-10-3000032||20101210141652||MA|F||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384297^URINE BACTERIAL CULTURE^L01N||*****Microbiology Urine*****|||A|||F|||20101210141652OBX|2|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|3|TX|4384297^URINE BACTERIAL CULTURE^L01N||                     TEST: Urine Culture|||A|||F|||20101210141652OBX|4|TX|4384297^URINE BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Urine                    COLLECTED: 12/10/2010 14:00 MST|||A|||F|||20101210141652OBX|5|TX|4384297^URINE BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Post Pros. Massage Urine  RECEIVED: 12/10/2010 14:05 MST|||A|||F|||20101210141652OBX|6|TX|4384297^URINE BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: R/O YEAST                ACCESSION: UR-10-3000032|||A|||F|||20101210141652OBX|7|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|8|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|9|TX|4384297^URINE BACTERIAL CULTURE^L01N||     FINAL REPORT                                    Verified:12/10/2010 14:16 MST|||A|||F|||20101210141652OBX|10|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count greater than 1X10E8 cfu/L Escherichia coli|||A|||F|||20101210141652OBX|11|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count 1X10E7 - 1X10E8 cfu/L Staphylococcus aureus|||A|||F|||20101210141652OBX|12|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|13|TX|4384297^URINE BACTERIAL CULTURE^L01N||     SUSCEPTIBILITY RESULTS ***|||A|||F|||20101210141652OBX|14|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Escherichia|||A|||F|||20101210141652OBX|15|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             coli|||A|||F|||20101210141652OBX|16|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|17|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||F|||20101210141652OBX|18|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||F|||20101210141652OBX|19|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ampicillin              S|||A|||F|||20101210141652OBX|20|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalothin(1)          S|||A|||F|||20101210141652OBX|21|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefazolin(1)            S|||A|||F|||20101210141652OBX|22|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefepime(1)             R|||A|||F|||20101210141652OBX|23|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ceftriaxone(1)          R|||A|||F|||20101210141652OBX|24|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Gentamicin              S|||A|||F|||20101210141652OBX|25|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||F|||20101210141652OBX|26|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Norfloxacin             S|||A|||F|||20101210141652OBX|27|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||F|||20101210141652OBX|28|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|29|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|30|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|31|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|32|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Staphylococcus|||A|||F|||20101210141652OBX|33|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             aureus|||A|||F|||20101210141652OBX|34|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|35|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||F|||20101210141652OBX|36|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||F|||20101210141652OBX|37|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||F|||20101210141652OBX|38|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||F|||20101210141652OBX|39|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ciprofloxacin           S|||A|||F|||20101210141652OBX|40|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|41|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|42|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|43|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|44|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|45|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|46|TX|4384297^URINE BACTERIAL CULTURE^L01N||     *** SUSCEPTIBILITY FOOTNOTES|||A|||F|||20101210141652OBX|47|TX|4384297^URINE BACTERIAL CULTURE^L01N||     (1)|||A|||F|||20101210141652OBX|48|TX|4384297^URINE BACTERIAL CULTURE^L01N||     This organism has been shown to produce an Extended Spectrum Beta|||A|||F|||20101210141652OBX|49|TX|4384297^URINE BACTERIAL CULTURE^L01N||     lactamase (ESBL) and should be considered resistant to all|||A|||F|||20101210141652OBX|50|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalosporins.|||A|||F|||20101210141652OBX|51|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|52|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|53|TX|4384297^URINE BACTERIAL CULTURE^L01N||     __________________________________________________________|||A|||F|||20101210141652
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141652||ORU^R01|Q199822870T198319943|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450795^101MA|2922077^URINE BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140400|URINE^^R/O YEAST|1001745^Test, Physician - p-Test Physician||||UR-10-3000032||20101210141652||MA|F||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384297^URINE BACTERIAL CULTURE^L01N||*****Microbiology Urine*****|||A|||F|||20101210141652OBX|2|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|3|TX|4384297^URINE BACTERIAL CULTURE^L01N||                     TEST: Urine Culture|||A|||F|||20101210141652OBX|4|TX|4384297^URINE BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Urine                    COLLECTED: 12/10/2010 14:00 MST|||A|||F|||20101210141652OBX|5|TX|4384297^URINE BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Post Pros. Massage Urine  RECEIVED: 12/10/2010 14:05 MST|||A|||F|||20101210141652OBX|6|TX|4384297^URINE BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: R/O YEAST                ACCESSION: UR-10-3000032|||A|||F|||20101210141652OBX|7|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|8|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|9|TX|4384297^URINE BACTERIAL CULTURE^L01N||     FINAL REPORT                                    Verified:12/10/2010 14:16 MST|||A|||F|||20101210141652OBX|10|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count greater than 1X10E8 cfu/L Escherichia coli|||A|||F|||20101210141652OBX|11|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count 1X10E7 - 1X10E8 cfu/L Staphylococcus aureus|||A|||F|||20101210141652OBX|12|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|13|TX|4384297^URINE BACTERIAL CULTURE^L01N||     SUSCEPTIBILITY RESULTS ***|||A|||F|||20101210141652OBX|14|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Escherichia|||A|||F|||20101210141652OBX|15|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             coli|||A|||F|||20101210141652OBX|16|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|17|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||F|||20101210141652OBX|18|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||F|||20101210141652OBX|19|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ampicillin              S|||A|||F|||20101210141652OBX|20|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalothin(1)          S|||A|||F|||20101210141652OBX|21|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefazolin(1)            S|||A|||F|||20101210141652OBX|22|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefepime(1)             R|||A|||F|||20101210141652OBX|23|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ceftriaxone(1)          R|||A|||F|||20101210141652OBX|24|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Gentamicin              S|||A|||F|||20101210141652OBX|25|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||F|||20101210141652OBX|26|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Norfloxacin             S|||A|||F|||20101210141652OBX|27|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||F|||20101210141652OBX|28|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|29|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|30|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|31|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|32|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Staphylococcus|||A|||F|||20101210141652OBX|33|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             aureus|||A|||F|||20101210141652OBX|34|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|35|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||F|||20101210141652OBX|36|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||F|||20101210141652OBX|37|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||F|||20101210141652OBX|38|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||F|||20101210141652OBX|39|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ciprofloxacin           S|||A|||F|||20101210141652OBX|40|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|41|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|42|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|43|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|44|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|45|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|46|TX|4384297^URINE BACTERIAL CULTURE^L01N||     *** SUSCEPTIBILITY FOOTNOTES|||A|||F|||20101210141652OBX|47|TX|4384297^URINE BACTERIAL CULTURE^L01N||     (1)|||A|||F|||20101210141652OBX|48|TX|4384297^URINE BACTERIAL CULTURE^L01N||     This organism has been shown to produce an Extended Spectrum Beta|||A|||F|||20101210141652OBX|49|TX|4384297^URINE BACTERIAL CULTURE^L01N||     lactamase (ESBL) and should be considered resistant to all|||A|||F|||20101210141652OBX|50|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalosporins.|||A|||F|||20101210141652OBX|51|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|52|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||F|||20101210141652OBX|53|TX|4384297^URINE BACTERIAL CULTURE^L01N||     __________________________________________________________|||A|||F|||20101210141652
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210141804||ORU^R01|Q199822873T198319946|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450792^101MA|2922080^WOUND BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140200|Superficial Wound Swab^^right hand|1001745^Test, Physician - p-Test Physician||||WN-10-3000020||20101210141746||MA|P||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384298^WOUND BACTERIAL CULTURE^L01N||*****Microbiology Wound/Abscess*****|||A|||P|||20101210141746OBX|2|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|3|TX|4384298^WOUND BACTERIAL CULTURE^L01N||                     TEST: Wound Culture|||A|||P|||20101210141746OBX|4|TX|4384298^WOUND BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Superficial Wound Swab   COLLECTED: 12/10/2010 14:00 MST|||A|||P|||20101210141746OBX|5|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Finger                    RECEIVED: 12/10/2010 14:05 MST|||A|||P|||20101210141746OBX|6|TX|4384298^WOUND BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: right hand               ACCESSION: WN-10-3000020|||A|||P|||20101210141746OBX|7|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|8|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|9|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|10|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     GRAM STAIN REPORT                               Verified:12/10/2010 14:10 MST|||A|||P|||20101210141746OBX|11|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No neutrophils seen|||A|||P|||20101210141746OBX|12|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No epithelial cells seen|||A|||P|||20101210141746OBX|13|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     No organisms seen|||A|||P|||20101210141746OBX|14|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|15|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|16|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     PRELIMINARY REPORT                              Verified:12/10/2010 14:17 MST|||A|||P|||20101210141746OBX|17|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     Coagulase negative Staphylococcus, not S.saprophyticus|||A|||P|||20101210141746OBX|18|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|19|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|20|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     Additional info / info provided on requisition:|||A|||P|||20101210141746OBX|21|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     D1|||A|||P|||20101210141746OBX|22|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|23|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|24|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|25|TX|4384298^WOUND BACTERIAL CULTURE^L01N|||||A|||P|||20101210141746OBX|26|TX|4384298^WOUND BACTERIAL CULTURE^L01N||     __________________________________________________________|||A|||P|||20101210141746
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210142056||ORU^R01|Q199822876T198319949|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450795^101MA|2922077^URINE BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140400|URINE^^R/O YEAST|1001745^Test, Physician - p-Test Physician||||UR-10-3000032||20101210142045||MA|C||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384297^URINE BACTERIAL CULTURE^L01N||*****Microbiology Urine*****|||A|||C|||20101210142045OBX|2|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|3|TX|4384297^URINE BACTERIAL CULTURE^L01N||                     TEST: Urine Culture|||A|||C|||20101210142045OBX|4|TX|4384297^URINE BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Urine                    COLLECTED: 12/10/2010 14:00 MST|||A|||C|||20101210142045OBX|5|TX|4384297^URINE BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Post Pros. Massage Urine  RECEIVED: 12/10/2010 14:05 MST|||A|||C|||20101210142045OBX|6|TX|4384297^URINE BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: R/O YEAST                ACCESSION: UR-10-3000032|||A|||C|||20101210142045OBX|7|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|8|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|9|TX|4384297^URINE BACTERIAL CULTURE^L01N||     FINAL REPORT                                    Verified:12/10/2010 14:16 MST|||A|||C|||20101210142045OBX|10|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count greater than 1X10E8 cfu/L Escherichia coli|||A|||C|||20101210142045OBX|11|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count 1X10E7 - 1X10E8 cfu/L Staphylococcus aureus|||A|||C|||20101210142045OBX|12|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|13|TX|4384297^URINE BACTERIAL CULTURE^L01N||     SUSCEPTIBILITY RESULTS ***|||A|||C|||20101210142045OBX|14|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Escherichia|||A|||C|||20101210142045OBX|15|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             coli|||A|||C|||20101210142045OBX|16|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|17|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||C|||20101210142045OBX|18|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||C|||20101210142045OBX|19|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ampicillin              S|||A|||C|||20101210142045OBX|20|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalothin(1)          S|||A|||C|||20101210142045OBX|21|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefazolin(1)            S|||A|||C|||20101210142045OBX|22|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefepime(1)             R|||A|||C|||20101210142045OBX|23|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ceftriaxone(1)          R|||A|||C|||20101210142045OBX|24|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Gentamicin              S|||A|||C|||20101210142045OBX|25|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||C|||20101210142045OBX|26|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Norfloxacin             S|||A|||C|||20101210142045OBX|27|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||C|||20101210142045OBX|28|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|29|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|30|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|31|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|32|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Staphylococcus|||A|||C|||20101210142045OBX|33|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             aureus|||A|||C|||20101210142045OBX|34|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|35|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||C|||20101210142045OBX|36|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||C|||20101210142045OBX|37|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||C|||20101210142045OBX|38|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      R#|||A|||C|||20101210142045OBX|39|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ciprofloxacin           S|||A|||C|||20101210142045OBX|40|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|41|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|42|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|43|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Staphylococcus aureus|||A|||C|||20101210142045OBX|44|TX|4384297^URINE BACTERIAL CULTURE^L01N||     _____________________|||A|||C|||20101210142045OBX|45|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa Interp corrected from S on 12/10/2010 14:20 MST|||A|||C|||20101210142045OBX|46|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|47|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|48|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|49|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|50|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|51|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|52|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|53|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|54|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|55|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|56|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|57|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|58|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|59|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|60|TX|4384297^URINE BACTERIAL CULTURE^L01N||     *** SUSCEPTIBILITY FOOTNOTES|||A|||C|||20101210142045OBX|61|TX|4384297^URINE BACTERIAL CULTURE^L01N||     (1)|||A|||C|||20101210142045OBX|62|TX|4384297^URINE BACTERIAL CULTURE^L01N||     This organism has been shown to produce an Extended Spectrum Beta|||A|||C|||20101210142045OBX|63|TX|4384297^URINE BACTERIAL CULTURE^L01N||     lactamase (ESBL) and should be considered resistant to all|||A|||C|||20101210142045OBX|64|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalosporins.|||A|||C|||20101210142045OBX|65|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|66|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142045OBX|67|TX|4384297^URINE BACTERIAL CULTURE^L01N||     __________________________________________________________|||A|||C|||20101210142045
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101210142320||ORU^R01|Q199822879T198319952|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176450795^101MA|2922077^URINE BACTERIAL CULTURE^L01N|||20101210140000|||||||20101210140400|URINE^^R/O YEAST|1001745^Test, Physician - p-Test Physician||||UR-10-3000032||20101210142315||MA|C||1^^^20101210140000^^RT~^^^^^RT|OBX|1|TX|4384297^URINE BACTERIAL CULTURE^L01N||*****Microbiology Urine*****|||A|||C|||20101210142315OBX|2|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|3|TX|4384297^URINE BACTERIAL CULTURE^L01N||                     TEST: Urine Culture|||A|||C|||20101210142315OBX|4|TX|4384297^URINE BACTERIAL CULTURE^L01N||            SPECIMEN TYPE: Urine                    COLLECTED: 12/10/2010 14:00 MST|||A|||C|||20101210142315OBX|5|TX|4384297^URINE BACTERIAL CULTURE^L01N||          SPECIMEN SOURCE: Post Pros. Massage Urine  RECEIVED: 12/10/2010 14:05 MST|||A|||C|||20101210142315OBX|6|TX|4384297^URINE BACTERIAL CULTURE^L01N||          ADDITIONAL INFO: R/O YEAST                ACCESSION: UR-10-3000032|||A|||C|||20101210142315OBX|7|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|8|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|9|TX|4384297^URINE BACTERIAL CULTURE^L01N||     ADDITIONAL/AMENDED REPORT                       Verified:12/10/2010 14:23 MST|||A|||C|||20101210142315OBX|10|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count greater than 1X10E8 cfu/L Escherichia coli|||A|||C|||20101210142315OBX|11|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Colony count 1X10E7 - 1X10E8 cfu/L Staphylococcus aureus|||A|||C|||20101210142315OBX|12|TX|4384297^URINE BACTERIAL CULTURE^L01N||     **Note amended susceptibility result**|||A|||C|||20101210142315OBX|13|TX|4384297^URINE BACTERIAL CULTURE^L01N||     ***Add Freetext*** resistant susceptible to resistant|||A|||C|||20101210142315OBX|14|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|15|TX|4384297^URINE BACTERIAL CULTURE^L01N||     SUSCEPTIBILITY RESULTS ***|||A|||C|||20101210142315OBX|16|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Escherichia|||A|||C|||20101210142315OBX|17|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             coli|||A|||C|||20101210142315OBX|18|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|19|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||C|||20101210142315OBX|20|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||C|||20101210142315OBX|21|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ampicillin              S|||A|||C|||20101210142315OBX|22|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalothin(1)          S|||A|||C|||20101210142315OBX|23|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefazolin(1)            S|||A|||C|||20101210142315OBX|24|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cefepime(1)             R|||A|||C|||20101210142315OBX|25|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ceftriaxone(1)          R|||A|||C|||20101210142315OBX|26|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Gentamicin              S|||A|||C|||20101210142315OBX|27|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||C|||20101210142315OBX|28|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Norfloxacin             S|||A|||C|||20101210142315OBX|29|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      S|||A|||C|||20101210142315OBX|30|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|31|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|32|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|33|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|34|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Staphylococcus|||A|||C|||20101210142315OBX|35|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             aureus|||A|||C|||20101210142315OBX|36|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|37|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             Interp|||A|||C|||20101210142315OBX|38|TX|4384297^URINE BACTERIAL CULTURE^L01N||                             _________|||A|||C|||20101210142315OBX|39|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Nitrofurantoin          S|||A|||C|||20101210142315OBX|40|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa      R#|||A|||C|||20101210142315OBX|41|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Ciprofloxacin           S|||A|||C|||20101210142315OBX|42|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|43|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|44|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|45|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Staphylococcus aureus|||A|||C|||20101210142315OBX|46|TX|4384297^URINE BACTERIAL CULTURE^L01N||     _____________________|||A|||C|||20101210142315OBX|47|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Trimethoprim/Sulfa Interp corrected from S on 12/10/2010 14:20 MST|||A|||C|||20101210142315OBX|48|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|49|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|50|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|51|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|52|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|53|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|54|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|55|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|56|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|57|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|58|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|59|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|60|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|61|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|62|TX|4384297^URINE BACTERIAL CULTURE^L01N||     *** SUSCEPTIBILITY FOOTNOTES|||A|||C|||20101210142315OBX|63|TX|4384297^URINE BACTERIAL CULTURE^L01N||     (1)|||A|||C|||20101210142315OBX|64|TX|4384297^URINE BACTERIAL CULTURE^L01N||     This organism has been shown to produce an Extended Spectrum Beta|||A|||C|||20101210142315OBX|65|TX|4384297^URINE BACTERIAL CULTURE^L01N||     lactamase (ESBL) and should be considered resistant to all|||A|||C|||20101210142315OBX|66|TX|4384297^URINE BACTERIAL CULTURE^L01N||     Cephalosporins.|||A|||C|||20101210142315OBX|67|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|68|TX|4384297^URINE BACTERIAL CULTURE^L01N|||||A|||C|||20101210142315OBX|69|TX|4384297^URINE BACTERIAL CULTURE^L01N||     __________________________________________________________|||A|||C|||20101210142315
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214100421||ORU^R01|Q199823599T198320671|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452155^101AP|313048^NON-GYN CYTOLOGY REPORT^L01N|||20101214095100|||||||20101214095100|^^Liver FNA|1001745^Test, Physician - p-Test Physician||||NF-10-0007545||20101214100357||AP|F||1^^^20101214095100^^~^^^^^RT|OBX|1|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||*****Surgical Pathology Report*****||||||F|||20101214100357OBX|2|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|3|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Accession Number     NF-10-0007545||||||F|||20101214100357OBX|4|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Collected Date/Time  2010-12-14 09:51 MST||||||F|||20101214100357OBX|5|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Received Date/Time   2010-12-14 09:51 MST||||||F|||20101214100357OBX|6|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214100357OBX|7|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|8|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|9|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Clinical Information||||||F|||20101214100357OBX|10|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      None||||||F|||20101214100357OBX|11|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|12|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|13|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Specimen||||||F|||20101214100357OBX|14|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Liver FNA||||||F|||20101214100357OBX|15|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|16|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|17|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Gross Description||||||F|||20101214100357OBX|18|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      2 ml of yellow fluid is received.||||||F|||20101214100357OBX|19|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|20|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|21|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Diagnosis||||||F|||20101214100357OBX|22|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      MALIGNANT CELLS PRESENT. Features are consistent with a metastatic adenocarcinoma.||||||F|||20101214100357OBX|23|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|24|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Screened by: CG||||||F|||20101214100357OBX|25|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|26|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Reported by: Gates, Colleen||||||F|||20101214100357OBX|27|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||                            (Electronically signed by)||||||F|||20101214100357OBX|28|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||                            2010/12/14 10:03||||||F|||20101214100357OBX|29|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|30|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|31|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Comment||||||F|||20101214100357OBX|32|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      Metastatic adenocarcinoma consistemt with Lung Primary.||||||F|||20101214100357OBX|33|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|34|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100357OBX|35|TX|4187233^NON-GYN CYTOLOGY REPORT^L01N||      *****Microbiology Wound/Abscess*****||||||F|||20101214100357
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214100752||ORU^R01|Q199823608T198320680|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452185^101AP|313050^CYTOPATHOLOGY REPORT^L01N|||20101214100500|||||||20101214100500|^^Cervical Sample LBC|1001745^Test, Physician - p-Test Physician||||GH-10-0152011||20101214100749||AP|F||1^^^20101214100500^^~^^^^^RT|OBX|1|TX|4187232^GYN CYTOLOGY REPORT^L01N||*****Gyn Cytopathology Report*****||||||F|||20101214100749OBX|2|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|3|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Accession Number     GH-10-0152011||||||F|||20101214100749OBX|4|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Collected Date/Time  2010-12-14 10:05 MST||||||F|||20101214100749OBX|5|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Received Date/Time   2010-12-14 10:05 MST||||||F|||20101214100749OBX|6|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214100749OBX|7|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|8|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|9|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Clinical Information||||||F|||20101214100749OBX|10|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Date of LMP: n/a||||||F|||20101214100749OBX|11|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|12|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|13|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Specimen||||||F|||20101214100749OBX|14|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Cervical Sample LBC||||||F|||20101214100749OBX|15|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|16|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|17|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Specimen Adequacy:||||||F|||20101214100749OBX|18|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Satisfactory for Evaluation.  Transformation Zone Present.||||||F|||20101214100749OBX|19|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|20|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|21|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Diagnosis:||||||F|||20101214100749OBX|22|TX|4187232^GYN CYTOLOGY REPORT^L01N||      EPITHELIAL CELL ABNORMALITY - Low-Grade Squamous Intraepithelial Lesion (LSIL).||||||F|||20101214100749OBX|23|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|24|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|25|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Recommendation:||||||F|||20101214100749OBX|26|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Repeat the smear in 6 months.||||||F|||20101214100749OBX|27|TX|4187232^GYN CYTOLOGY REPORT^L01N||      You may need to modify the recommendation based on your clinical assessment and||||||F|||20101214100749OBX|28|TX|4187232^GYN CYTOLOGY REPORT^L01N||      judgement.  Please refer to the Alberta Cervical Cancer Screening Program (ACCSP)||||||F|||20101214100749OBX|29|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Clinical Practice Guidelines for patient management at www.topalbertadoctors.org.||||||F|||20101214100749OBX|30|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|31|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Screened by: CG||||||F|||20101214100749OBX|32|TX|4187232^GYN CYTOLOGY REPORT^L01N||||||||F|||20101214100749OBX|33|TX|4187232^GYN CYTOLOGY REPORT^L01N||      Reported by: Gates, Colleen||||||F|||20101214100749OBX|34|TX|4187232^GYN CYTOLOGY REPORT^L01N||                            (Electronically signed by)||||||F|||20101214100749OBX|35|TX|4187232^GYN CYTOLOGY REPORT^L01N||                            2010/12/14 10:07||||||F|||20101214100749
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214104054||ORU^R01|Q199823626T198320698|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452202^101AP|313046^SURGICAL PATHOLOGY REPORT^L01N|||20101214102300|||||||20101214102300|^^LN, Regional Resection(5)|1001745^Test, Physician - p-Test Physician||||SF-10-0020326||20101214104043||AP|F||1^^^20101214102300^^~^^^^^RT|OBX|1|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||*****Surgical Pathology Report*****||||||F|||20101214104043OBX|2|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|3|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Accession Number     SF-10-0020326||||||F|||20101214104043OBX|4|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Collected Date/Time  2010-12-14 10:23 MST||||||F|||20101214104043OBX|5|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Received Date/Time   2010-12-14 10:23 MST||||||F|||20101214104043OBX|6|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214104043OBX|7|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|8|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|9|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Specimen Description||||||F|||20101214104043OBX|10|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      A.  Inferior pulmonary ligament node||||||F|||20101214104043OBX|11|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B.  Right lower lobe superior segment||||||F|||20101214104043OBX|12|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      C.  Right middle lobe wedge resection||||||F|||20101214104043OBX|13|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      D.  #10R lymph node||||||F|||20101214104043OBX|14|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      E.  Subcarinal #7 lymph node||||||F|||20101214104043OBX|15|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      F.  #12 right upper lobe node||||||F|||20101214104043OBX|16|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G.  Right upper lobe posterior segment *please note 2 nodules*||||||F|||20101214104043OBX|17|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|18|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|19|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Clinical Information||||||F|||20101214104043OBX|20|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Smoker, enlarging RUL nodule, incidental RML nodule - query metastatic lung Ca.||||||F|||20101214104043OBX|21|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|22|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214104043OBX|23|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      __||||||F|||20101214104043OBX|24|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|25|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|26|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Diagnosis||||||F|||20101214104043OBX|27|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      A.  Inferior Pulmonary Ligament Node:||||||F|||20101214104043OBX|28|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214104043OBX|29|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|30|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B.  Right Lower Lobe Superior Segment:||||||F|||20101214104043OBX|31|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Moderately differentiated adenocarcinoma (1.4 cm),with areas of||||||F|||20101214104043OBX|32|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  bronchiolo-alveolar carcinoma like growth pattern.||||||F|||20101214104043OBX|33|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Arises in a background of respiratory bronchiolitis, congestion and||||||F|||20101214104043OBX|34|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                   mild emphysematous change.||||||F|||20101214104043OBX|35|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Resection margins negative for malignancy and dysplasia||||||F|||20101214104043OBX|36|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Pleura free of tumor.||||||F|||20101214104043OBX|37|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|38|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      C.  Right Middle Lobe Wedge Resection:||||||F|||20101214104043OBX|39|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Hyalinized fibrous nodule with chronic inflammatory cells.||||||F|||20101214104043OBX|40|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Negative for Malignancy and Dysplasia.||||||F|||20101214104043OBX|41|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|42|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      D.  #10 R Lymph Node:||||||F|||20101214104043OBX|43|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214104043OBX|44|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|45|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      E.  Subcarinal #7 Lymph Node:||||||F|||20101214104043OBX|46|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214104043OBX|47|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|48|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      F.  #12 Right Upper Lobe Node:||||||F|||20101214104043OBX|49|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214104043OBX|50|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|51|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G.  Right Upper Lobe, Posterior Segment:||||||F|||20101214104043OBX|52|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            -     1)Moderately differentiated adenocarcinoma (1.7 cm) in a||||||F|||20101214104043OBX|53|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  background of respiratory bronchiolitis and emphysematous change||||||F|||20101214104043OBX|54|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|55|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|56|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|57|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|58|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|59|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|60|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|61|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Tumor is morphologically different than that in specimen B and thus||||||F|||20101214104043OBX|62|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  is reflective of a second primary site.||||||F|||20101214104043OBX|63|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|64|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  2)Moderately differentiated adenocarcinoma (2.0 cm),with areas of||||||F|||20101214104043OBX|65|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  bronchiolo-alveolar carcinoma like growth pattern.||||||F|||20101214104043OBX|66|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Arises in a background of respiratory bronchiolitis, congestion and||||||F|||20101214104043OBX|67|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                   mild emphysematous change.||||||F|||20101214104043OBX|68|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|69|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  Tumor is morphologically the same as that seen in specimen B but||||||F|||20101214104043OBX|70|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  different from the first tumor in specimen G. Thus reflective of||||||F|||20101214104043OBX|71|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  pulmonary metastases.||||||F|||20101214104043OBX|72|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|73|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  3) One microscopic area of Bronchioalveolar Carcinoma (0.6 cm)||||||F|||20101214104043OBX|74|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|75|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  4)  Atypical adenomatous hyperplasia (AAH)||||||F|||20101214104043OBX|76|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|77|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                  5) Resection margins negative for malignancy and dysplasia||||||F|||20101214104043OBX|78|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||                      Pleura free of tumor.||||||F|||20101214104043OBX|79|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|80|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214104043OBX|81|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|82|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214104043OBX|83|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Verified: 2010/12/14 10:40 AM||||||F|||20101214104043OBX|84|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      CG/CG||||||F|||20101214104043OBX|85|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|86|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214104043OBX|87|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      ________||||||F|||20101214104043OBX|88|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|89|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|90|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Synoptic Report||||||F|||20101214104043OBX|91|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G: CLS Lung Resection||||||F|||20101214104043OBX|92|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Specimen Type:||||||F|||20101214104043OBX|93|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Wedge resection||||||F|||20101214104043OBX|94|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Laterality:||||||F|||20101214104043OBX|95|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Right||||||F|||20101214104043OBX|96|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor Site:||||||F|||20101214104043OBX|97|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Upper lobe||||||F|||20101214104043OBX|98|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor type:||||||F|||20101214104043OBX|99|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Adenocarcinoma||||||F|||20101214104043OBX|100|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Grade:||||||F|||20101214104043OBX|101|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Moderately differentiated||||||F|||20101214104043OBX|102|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Location:||||||F|||20101214104043OBX|103|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Peripheral||||||F|||20101214104043OBX|104|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Satellite nodules in same lobe:||||||F|||20101214104043OBX|105|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Positive||||||F|||20101214104043OBX|106|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Intrapulmonary metastases:||||||F|||20101214104043OBX|107|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Positive||||||F|||20101214104043OBX|108|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Vascular invasion:||||||F|||20101214104043OBX|109|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|110|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Perineural invasion:||||||F|||20101214104043OBX|111|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|112|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Margins: - Bronchial:||||||F|||20101214104043OBX|113|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor 0.5 cm away from stapled resection margin||||||F|||20101214104043OBX|114|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Margins: - Medistinal:||||||F|||20101214104043OBX|115|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|116|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|117|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|118|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|119|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|120|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|121|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|122|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Pleural invasion:||||||F|||20101214104043OBX|123|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|124|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Atelectasis/Obstructive Pneumonia:||||||F|||20101214104043OBX|125|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|126|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Lymph nodes||||||F|||20101214104043OBX|127|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|128|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B: CLS Lung Resection||||||F|||20101214104043OBX|129|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Specimen Type:||||||F|||20101214104043OBX|130|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Wedge resection||||||F|||20101214104043OBX|131|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Laterality:||||||F|||20101214104043OBX|132|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Right||||||F|||20101214104043OBX|133|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor Site:||||||F|||20101214104043OBX|134|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Lower lobe||||||F|||20101214104043OBX|135|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor type:||||||F|||20101214104043OBX|136|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Adenocarcinoma||||||F|||20101214104043OBX|137|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Grade:||||||F|||20101214104043OBX|138|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Moderately differentiated||||||F|||20101214104043OBX|139|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Location:||||||F|||20101214104043OBX|140|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Peripheral||||||F|||20101214104043OBX|141|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Size:||||||F|||20101214104043OBX|142|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Maximum dimension  1.4  cm||||||F|||20101214104043OBX|143|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Satellite nodules in same lobe:||||||F|||20101214104043OBX|144|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|145|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Vascular invasion:||||||F|||20101214104043OBX|146|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|147|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Perineural invasion:||||||F|||20101214104043OBX|148|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|149|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Margins: - Bronchial:||||||F|||20101214104043OBX|150|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Tumor 1.5 cm away from stapled resection margin||||||F|||20101214104043OBX|151|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Pleural invasion:||||||F|||20101214104043OBX|152|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|153|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Atelectasis/Obstructive Pneumonia:||||||F|||20101214104043OBX|154|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|155|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      In situ component:||||||F|||20101214104043OBX|156|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|157|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Lymph nodes:||||||F|||20101214104043OBX|158|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Negative||||||F|||20101214104043OBX|159|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|160|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|161|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Gross Description||||||F|||20101214104043OBX|162|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Received are specimens A to G.  All requisitions and specimen containers are labelled||||||F|||20101214104043OBX|163|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      with the patient's name.  The cassettes and AP identifiers are labelled with the Surgical||||||F|||20101214104043OBX|164|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Number SF10-19864.||||||F|||20101214104043OBX|165|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|166|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      A.  Received is a single grey/tan irregular soft tissue nodule measuring 1.0 x 0.8 x 0.2||||||F|||20101214104043OBX|167|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      cm.  It is trisected and submitted in one block.  ARH/ct||||||F|||20101214104043OBX|168|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|169|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B.  The specimen consists of a lung wedge (10 x 6 x 2.5 cm) with a single yellow||||||F|||20101214104043OBX|170|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      spiculated nodule (1.0 cm) located 1.5 cm from the painted (black) staple margin.||||||F|||20101214104043OBX|171|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Representative section submitted for QS.  IC/ct||||||F|||20101214104043OBX|172|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|173|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Another stapled margin is identified opposite to the first.  The staples are cut and the||||||F|||20101214104043OBX|174|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      resection surface is painted blue.  The lung wedge is sectioned serially. The primary||||||F|||20101214104043OBX|175|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      tumor mass identified during the frozen section is seen.  No other tumor masses, areas of||||||F|||20101214104043OBX|176|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      consolidation or fibrosis are identified.  Sections are submitted as follows:||||||F|||20101214104043OBX|177|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|178|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|179|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|180|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|181|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|182|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|183|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|184|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B2-B3 sections of the primary tumor mass, submitted in toto||||||F|||20101214104043OBX|185|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B4-B6 representative sections of the lung parenchyma adjacent to the tumor mass||||||F|||20101214104043OBX|186|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B7-B10 random representative sections of the grossly normal-appearing lung parenchyma||||||F|||20101214104043OBX|187|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      ARH/ct||||||F|||20101214104043OBX|188|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|189|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      C.  The specimen consists of a lung wedge (3.5 x 2.5 x 0.5 cm) containing a single||||||F|||20101214104043OBX|190|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      subpleural nodule (0.1 cm and ? circled).  Staple resection margin painted black.  Nodule||||||F|||20101214104043OBX|191|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      submitted in toto for QS.  IC/ct||||||F|||20101214104043OBX|192|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|193|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      The remaining portion of the wedge was sectioned serially and appears to be grossly||||||F|||20101214104043OBX|194|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      normal.  Random representative sections will be submitted in blocks C2-C4.  ARH/ct||||||F|||20101214104043OBX|195|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|196|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      D.  Received is a single grey/tan irregular portion of soft tissue measuring 1.5 x 0.6 x||||||F|||20101214104043OBX|197|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      0.2 cm.  It is bisected longitudinally and submitted totally in one block.||||||F|||20101214104043OBX|198|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|199|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      E.  Received are two portions of irregular grey/tan tissue measuring in aggregate 1.2 x||||||F|||20101214104043OBX|200|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      0.8 x 0.3 cm.  Each of the portions are bisected longitudinally and submitted totally in||||||F|||20101214104043OBX|201|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      blocks E1 and E2.||||||F|||20101214104043OBX|202|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|203|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      F.  Received are multiple portions of grey/tan and irregular soft tissue measuring in||||||F|||20101214104043OBX|204|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      aggregate 1.5 x 1.3 x 0.2 cm.  The largest portion is bisected and submitted totally in||||||F|||20101214104043OBX|205|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      block F1.  The remaining portions are submitted totally in block F2.||||||F|||20101214104043OBX|206|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|207|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G.  Received is a wedge of lung tissue measuring 13.0 x 7.5 x 1.3 cm.  A stapled||||||F|||20101214104043OBX|208|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      resection margin is identified.  The stapled resection margin is painted blue.  The||||||F|||20101214104043OBX|209|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      pleural surface shows puckering, at a distance of 2.5 cm from the stapled margin.||||||F|||20101214104043OBX|210|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Underneath this puckered pleural surface, an irregular firm-to-hard nodule can be||||||F|||20101214104043OBX|211|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      palpated.  On serial sectioning of the lung wedge, a yellow/tan firm-to-hard irregular||||||F|||20101214104043OBX|212|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      nodule is identified coming within 0.2 cm of the pleural surface and 0.5 cm from the||||||F|||20101214104043OBX|213|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      stapled resection margin.  The mass itself measures 1.7 x 1.1 x 1.2 cm.  Another||||||F|||20101214104043OBX|214|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      irregular firm-to-hard yellow/tan mass is identified coming within 0.2 cm of the puckered||||||F|||20101214104043OBX|215|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      pleural surface.  This mass measures 2.0 x 1.1 x 1.1 cm.  This mass is located at a||||||F|||20101214104043OBX|216|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      distance of 1.7 cm from the first tumor mass (where the depth of the lung wedge is 4.5||||||F|||20101214104043OBX|217|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      cm).  The rest of the lung parenchyma appears to be grossly normal with no areas of||||||F|||20101214104043OBX|218|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      fibrosis or consolidation identified.  Sections are submitted as follows:||||||F|||20101214104043OBX|219|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|220|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G1-G3 sections of the primary tumor mass, submitted in toto||||||F|||20101214104043OBX|221|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G4 sections of the primary and secondary tumor mass to show the relationship between the||||||F|||20101214104043OBX|222|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      two (contiguous sections)||||||F|||20101214104043OBX|223|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G5-G7 representative sections of the secondary tumor mass to show its relationship with||||||F|||20101214104043OBX|224|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      puckered pleural surface||||||F|||20101214104043OBX|225|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      G8-G12 random representative sections of the grossly normal-appearing lung parenchyma||||||F|||20101214104043OBX|226|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      ARH/ct||||||F|||20101214104043OBX|227|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|228|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|229|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Frozen Section Diagnosis||||||F|||20101214104043OBX|230|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      B.  Right Lower Lobe Superior Segment:||||||F|||20101214104043OBX|231|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            - Well-differentiated adenocarcinoma with BAC features  /IC  Conf #65||||||F|||20101214104043OBX|232|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|233|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      C.  Right Middle Lobe Wedge:||||||F|||20101214104043OBX|234|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||            - Benign fibrous nodule, negative for malignancy  IC/ct  Conf #66||||||F|||20101214104043OBX|235|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|236|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Reported by: V V Falck||||||F|||20101214104043OBX|237|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|238|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|239|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|240|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|241|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|242|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|243|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||||||||F|||20101214104043OBX|244|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Pathologist Comment||||||F|||20101214104043OBX|245|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      Sections show insitu and invasive adenocarcinomas. One of the adenocarcinomas is distinct||||||F|||20101214104043OBX|246|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      from the rest and thus indicative of multiple primary tumors, however the remaining||||||F|||20101214104043OBX|247|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      tumors in the two separate lobes are histologically similar and consistent with pulmonary||||||F|||20101214104043OBX|248|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      metastases. As the lower lobe tumor is smaller than the upper lobe tumor and insitu||||||F|||20101214104043OBX|249|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      disease is noted in the upper lobe, the upper lobe would be regarded as the primary tumor||||||F|||20101214104043OBX|250|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      in this case. This means two separate primary tumors are present in the upper lobe with||||||F|||20101214104043OBX|251|TX|4187235^SURGICAL PATHOLOGY REPORT^L01N||      upper lobe and lower lobe metastases from one of the two primary tumors.||||||F|||20101214104043
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214104724||ORU^R01|Q199823629T198320701|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452155^101AP|313048^NON-GYN CYTOLOGY REPORT^L01N|||20101214095100|||||||20101214095100|^^Liver FNA|1001745^Test, Physician - p-Test Physician||||NF-10-0007545||20101214104725||AP|F||1^^^20101214095100^^~^^^^^RT|OBX|1|TX|4187228^ADDENDUM REPORT^L01N||*****Addendum Report*****||||||F|||20101214104725OBX|2|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|3|TX|4187228^ADDENDUM REPORT^L01N||      Accession Number     NF-10-0007545||||||F|||20101214104725OBX|4|TX|4187228^ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 09:51 MST||||||F|||20101214104725OBX|5|TX|4187228^ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 09:51 MST||||||F|||20101214104725OBX|6|TX|4187228^ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214104725OBX|7|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|8|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|9|TX|4187228^ADDENDUM REPORT^L01N||      Addendum Reason||||||F|||20101214104725OBX|10|TX|4187228^ADDENDUM REPORT^L01N||      Testing Netcare and POS.||||||F|||20101214104725OBX|11|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|12|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|13|TX|4187228^ADDENDUM REPORT^L01N||      Addendum Diagnosis||||||F|||20101214104725OBX|14|TX|4187228^ADDENDUM REPORT^L01N||      No change in original diagnosis.||||||F|||20101214104725OBX|15|TX|4187228^ADDENDUM REPORT^L01N||            FNA, showing metastatic adenocarcinoma.||||||F|||20101214104725OBX|16|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|17|TX|4187228^ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214104725OBX|18|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|19|TX|4187228^ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214104725OBX|20|TX|4187228^ADDENDUM REPORT^L01N||      Verified: 2010/12/14 10:47 AM||||||F|||20101214104725OBX|21|TX|4187228^ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214104725OBX|22|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|23|TX|4187228^ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214104725OBX|24|TX|4187228^ADDENDUM REPORT^L01N||      ________||||||F|||20101214104725OBX|25|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|26|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|27|TX|4187228^ADDENDUM REPORT^L01N||      Addendum Discussion||||||F|||20101214104725OBX|28|TX|4187228^ADDENDUM REPORT^L01N||      No discussion.||||||F|||20101214104725OBX|29|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|30|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|31|TX|4187228^ADDENDUM REPORT^L01N||      *****Non-Gyn Cytopathology Report*****||||||F|||20101214104725OBX|32|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|33|TX|4187228^ADDENDUM REPORT^L01N||      Accession Number     NF-10-0007545||||||F|||20101214104725OBX|34|TX|4187228^ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 09:51 MST||||||F|||20101214104725OBX|35|TX|4187228^ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 09:51 MST||||||F|||20101214104725OBX|36|TX|4187228^ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214104725OBX|37|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|38|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|39|TX|4187228^ADDENDUM REPORT^L01N||      Clinical Information||||||F|||20101214104725OBX|40|TX|4187228^ADDENDUM REPORT^L01N||      None||||||F|||20101214104725OBX|41|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|42|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|43|TX|4187228^ADDENDUM REPORT^L01N||      Specimen||||||F|||20101214104725OBX|44|TX|4187228^ADDENDUM REPORT^L01N||      Liver FNA||||||F|||20101214104725OBX|45|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|46|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|47|TX|4187228^ADDENDUM REPORT^L01N||      Gross Description||||||F|||20101214104725OBX|48|TX|4187228^ADDENDUM REPORT^L01N||      2 ml of yellow fluid is received.||||||F|||20101214104725OBX|49|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|50|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|51|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|52|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|53|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|54|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|55|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|56|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|57|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|58|TX|4187228^ADDENDUM REPORT^L01N||      Diagnosis||||||F|||20101214104725OBX|59|TX|4187228^ADDENDUM REPORT^L01N||      MALIGNANT CELLS PRESENT. Features are consistent with a metastatic adenocarcinoma.||||||F|||20101214104725OBX|60|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|61|TX|4187228^ADDENDUM REPORT^L01N||      Screened by: CG||||||F|||20101214104725OBX|62|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|63|TX|4187228^ADDENDUM REPORT^L01N||      Reported by: Gates, Colleen||||||F|||20101214104725OBX|64|TX|4187228^ADDENDUM REPORT^L01N||                            (Electronically signed by)||||||F|||20101214104725OBX|65|TX|4187228^ADDENDUM REPORT^L01N||                            2010/12/14 10:03||||||F|||20101214104725OBX|66|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|67|TX|4187228^ADDENDUM REPORT^L01N||||||||F|||20101214104725OBX|68|TX|4187228^ADDENDUM REPORT^L01N||      Comment||||||F|||20101214104725OBX|69|TX|4187228^ADDENDUM REPORT^L01N||      Metastatic adenocarcinoma consistemt with Lung Primary.||||||F|||20101214104725
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214104908||ORU^R01|Q199823634T198320706|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452185^101AP|313050^CYTOPATHOLOGY REPORT^L01N|||20101214100500|||||||20101214100500|^^Cervical Sample LBC|1001745^Test, Physician - p-Test Physician||||GH-10-0152011||20101214104912||AP|F||1^^^20101214100500^^~^^^^^RT|OBX|1|TX|4788381^GYN ADDENDUM REPORT^L01N||*****Gyn Addendum Report*****||||||F|||20101214104912OBX|2|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|3|TX|4788381^GYN ADDENDUM REPORT^L01N||      Accession Number    GH-10-0152011||||||F|||20101214104912OBX|4|TX|4788381^GYN ADDENDUM REPORT^L01N||      Collected Date/Time 2010-12-14 10:05 MST||||||F|||20101214104912OBX|5|TX|4788381^GYN ADDENDUM REPORT^L01N||      Received Date/Time  2010-12-14 10:05 MST||||||F|||20101214104912OBX|6|TX|4788381^GYN ADDENDUM REPORT^L01N||      Pathologist         Gates, Colleen||||||F|||20101214104912OBX|7|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|8|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|9|TX|4788381^GYN ADDENDUM REPORT^L01N||      Addendum Reason||||||F|||20101214104912OBX|10|TX|4788381^GYN ADDENDUM REPORT^L01N||      Revision of diagnosis!||||||F|||20101214104912OBX|11|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|12|TX|4788381^GYN ADDENDUM REPORT^L01N||      PLEASE NOTE: This Addendum Report introduces a potentially significant change in the||||||F|||20101214104912OBX|13|TX|4788381^GYN ADDENDUM REPORT^L01N||      diagnosis or a change in patient information. Please clearly mark the Original Report as||||||F|||20101214104912OBX|14|TX|4788381^GYN ADDENDUM REPORT^L01N||      having been changed, with a clear reference to this Addendum Report (e.g. "Please see||||||F|||20101214104912OBX|15|TX|4788381^GYN ADDENDUM REPORT^L01N||      additional report").||||||F|||20101214104912OBX|16|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|17|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|18|TX|4788381^GYN ADDENDUM REPORT^L01N||      Addendum Diagnosis||||||F|||20101214104912OBX|19|TX|4788381^GYN ADDENDUM REPORT^L01N||      A: CLS GYN Addendum||||||F|||20101214104912OBX|20|TX|4788381^GYN ADDENDUM REPORT^L01N||      Specimen:||||||F|||20101214104912OBX|21|TX|4788381^GYN ADDENDUM REPORT^L01N||      Cervical Sample LBC.||||||F|||20101214104912OBX|22|TX|4788381^GYN ADDENDUM REPORT^L01N||      Specimen Adequacy:||||||F|||20101214104912OBX|23|TX|4788381^GYN ADDENDUM REPORT^L01N||      Satisfactory for Evaluation.||||||F|||20101214104912OBX|24|TX|4788381^GYN ADDENDUM REPORT^L01N||      Transformation Zone:||||||F|||20101214104912OBX|25|TX|4788381^GYN ADDENDUM REPORT^L01N||      Present.||||||F|||20101214104912OBX|26|TX|4788381^GYN ADDENDUM REPORT^L01N||      Diagnosis:||||||F|||20101214104912OBX|27|TX|4788381^GYN ADDENDUM REPORT^L01N||      Atypical Glandular Cells of Undetermined Significance (AGUS).||||||F|||20101214104912OBX|28|TX|4788381^GYN ADDENDUM REPORT^L01N||      Recommendation:||||||F|||20101214104912OBX|29|TX|4788381^GYN ADDENDUM REPORT^L01N||      Repeat the smear in 6 months.||||||F|||20101214104912OBX|30|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|31|TX|4788381^GYN ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214104912OBX|32|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|33|TX|4788381^GYN ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214104912OBX|34|TX|4788381^GYN ADDENDUM REPORT^L01N||      Verified: 2010/12/14 10:49 AM||||||F|||20101214104912OBX|35|TX|4788381^GYN ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214104912OBX|36|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|37|TX|4788381^GYN ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214104912OBX|38|TX|4788381^GYN ADDENDUM REPORT^L01N||      ________||||||F|||20101214104912OBX|39|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|40|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|41|TX|4788381^GYN ADDENDUM REPORT^L01N||      *****Gyn Cytopathology Report*****||||||F|||20101214104912OBX|42|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|43|TX|4788381^GYN ADDENDUM REPORT^L01N||      Accession Number     GH-10-0152011||||||F|||20101214104912OBX|44|TX|4788381^GYN ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 10:05 MST||||||F|||20101214104912OBX|45|TX|4788381^GYN ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 10:05 MST||||||F|||20101214104912OBX|46|TX|4788381^GYN ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214104912OBX|47|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|48|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|49|TX|4788381^GYN ADDENDUM REPORT^L01N||      Clinical Information||||||F|||20101214104912OBX|50|TX|4788381^GYN ADDENDUM REPORT^L01N||      Date of LMP: n/a||||||F|||20101214104912OBX|51|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|52|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|53|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|54|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|55|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|56|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|57|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|58|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|59|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|60|TX|4788381^GYN ADDENDUM REPORT^L01N||      Specimen||||||F|||20101214104912OBX|61|TX|4788381^GYN ADDENDUM REPORT^L01N||      Cervical Sample LBC||||||F|||20101214104912OBX|62|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|63|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|64|TX|4788381^GYN ADDENDUM REPORT^L01N||      Specimen Adequacy:||||||F|||20101214104912OBX|65|TX|4788381^GYN ADDENDUM REPORT^L01N||      Satisfactory for Evaluation.  Transformation Zone Present.||||||F|||20101214104912OBX|66|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|67|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|68|TX|4788381^GYN ADDENDUM REPORT^L01N||      Diagnosis:||||||F|||20101214104912OBX|69|TX|4788381^GYN ADDENDUM REPORT^L01N||      EPITHELIAL CELL ABNORMALITY - Low-Grade Squamous Intraepithelial Lesion (LSIL).||||||F|||20101214104912OBX|70|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|71|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|72|TX|4788381^GYN ADDENDUM REPORT^L01N||      Recommendation:||||||F|||20101214104912OBX|73|TX|4788381^GYN ADDENDUM REPORT^L01N||      Repeat the smear in 6 months.||||||F|||20101214104912OBX|74|TX|4788381^GYN ADDENDUM REPORT^L01N||      You may need to modify the recommendation based on your clinical assessment and||||||F|||20101214104912OBX|75|TX|4788381^GYN ADDENDUM REPORT^L01N||      judgement.  Please refer to the Alberta Cervical Cancer Screening Program (ACCSP)||||||F|||20101214104912OBX|76|TX|4788381^GYN ADDENDUM REPORT^L01N||      Clinical Practice Guidelines for patient management at www.topalbertadoctors.org.||||||F|||20101214104912OBX|77|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|78|TX|4788381^GYN ADDENDUM REPORT^L01N||      Screened by: CG||||||F|||20101214104912OBX|79|TX|4788381^GYN ADDENDUM REPORT^L01N||||||||F|||20101214104912OBX|80|TX|4788381^GYN ADDENDUM REPORT^L01N||      Reported by: Gates, Colleen||||||F|||20101214104912OBX|81|TX|4788381^GYN ADDENDUM REPORT^L01N||                            (Electronically signed by)||||||F|||20101214104912OBX|82|TX|4788381^GYN ADDENDUM REPORT^L01N||                            2010/12/14 10:07||||||F|||20101214104912
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214105653||ORU^R01|Q199823641T198320713|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452258^101AP|4388088^CONSULT REPORT^L01N|||20101214105300|||||||20101214105300|^^Outside Block/Slide|1000000^Unknown1, Physician, MD||||RF-10-0000900||20101214105651||AP|F||1^^^20101214105300^^~^^^^^RT|1001745^Test, Physician - p-Test PhysicianOBX|1|TX|4788372^CONSULT REPORT^L01N||*****Consultation Report*****||||||F|||20101214105651OBX|2|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|3|TX|4788372^CONSULT REPORT^L01N||      Accession Number     RF-10-0000900||||||F|||20101214105651OBX|4|TX|4788372^CONSULT REPORT^L01N||      Collected Date/Time  2010-12-14 10:53 MST||||||F|||20101214105651OBX|5|TX|4788372^CONSULT REPORT^L01N||      Received Date/Time   2010-12-14 10:53 MST||||||F|||20101214105651OBX|6|TX|4788372^CONSULT REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214105651OBX|7|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|8|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|9|TX|4788372^CONSULT REPORT^L01N||      Consult Description||||||F|||20101214105651OBX|10|TX|4788372^CONSULT REPORT^L01N||      Consult Specimen||||||F|||20101214105651OBX|11|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|12|TX|4788372^CONSULT REPORT^L01N||      Consult Type: TBCC Consult||||||F|||20101214105651OBX|13|TX|4788372^CONSULT REPORT^L01N||      Materials received:  21 Block  45 Slides||||||F|||20101214105651OBX|14|TX|4788372^CONSULT REPORT^L01N||      Received from:  PLC  Received by:  CG||||||F|||20101214105651OBX|15|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|16|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|17|TX|4788372^CONSULT REPORT^L01N||      Diagnosis||||||F|||20101214105651OBX|18|TX|4788372^CONSULT REPORT^L01N||      Abdominal Midline Mass, Core Biopsies:||||||F|||20101214105651OBX|19|TX|4788372^CONSULT REPORT^L01N||            -     High grade neuroendocrine carcinoma||||||F|||20101214105651OBX|20|TX|4788372^CONSULT REPORT^L01N||            -     (Extensive necrosis, prominent mitotic activity, Ki67 index greater||||||F|||20101214105651OBX|21|TX|4788372^CONSULT REPORT^L01N||                  than 50%)||||||F|||20101214105651OBX|22|TX|4788372^CONSULT REPORT^L01N||            -     Site of primary origin cannot be determined on histology (see micro||||||F|||20101214105651OBX|23|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|24|TX|4788372^CONSULT REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214105651OBX|25|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|26|TX|4788372^CONSULT REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214105651OBX|27|TX|4788372^CONSULT REPORT^L01N||      Verified: 2010/12/14 10:56 AM||||||F|||20101214105651OBX|28|TX|4788372^CONSULT REPORT^L01N||      CG/CG||||||F|||20101214105651OBX|29|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|30|TX|4788372^CONSULT REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214105651OBX|31|TX|4788372^CONSULT REPORT^L01N||      ________||||||F|||20101214105651OBX|32|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|33|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|34|TX|4788372^CONSULT REPORT^L01N||      Microscopic Description||||||F|||20101214105651OBX|35|TX|4788372^CONSULT REPORT^L01N||      This case was reviewed at the request of Dr. M. V, GI Oncology Group at the Tom Baker||||||F|||20101214105651OBX|36|TX|4788372^CONSULT REPORT^L01N||      Cancer Centre.  This patient has a midline upper abdominal mass which clinically would be||||||F|||20101214105651OBX|37|TX|4788372^CONSULT REPORT^L01N||      most consistent with a gallbladder carcinoma. Specific question in this review is whether||||||F|||20101214105651OBX|38|TX|4788372^CONSULT REPORT^L01N||      the possibility of a pancreatic primary as suggested originally, or other site of primary||||||F|||20101214105651OBX|39|TX|4788372^CONSULT REPORT^L01N||      is more likely.||||||F|||20101214105651OBX|40|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|41|TX|4788372^CONSULT REPORT^L01N||      This biopsy specimen consisted of two cores of tissue that consist of fibrous tissue and||||||F|||20101214105651OBX|42|TX|4788372^CONSULT REPORT^L01N||      necrotic areas with only small foci of residual viable neoplastic epithelium.  This||||||F|||20101214105651OBX|43|TX|4788372^CONSULT REPORT^L01N||      appears to be arranged into vague nests focally showing small intercellular lumina. There||||||F|||20101214105651OBX|44|TX|4788372^CONSULT REPORT^L01N||      appears to be a peripheral arrangement of nuclei and many of the nuclei have a granular||||||F|||20101214105651OBX|45|TX|4788372^CONSULT REPORT^L01N||      chromatin in a pattern raising the possibility of neuroendocrine tumor.  However, there||||||F|||20101214105651OBX|46|TX|4788372^CONSULT REPORT^L01N||      is prominent mitotic activity (three or more per high power field on the limited||||||F|||20101214105651OBX|47|TX|4788372^CONSULT REPORT^L01N||      material) and moderate nuclear pleomorphism. A positive synaptophysin immunostain||||||F|||20101214105651OBX|48|TX|4788372^CONSULT REPORT^L01N||      supports neuroendocrine differentiation.  I have also done a Ki67 which shows nuclear||||||F|||20101214105651OBX|49|TX|4788372^CONSULT REPORT^L01N||      positivity in approximately 50% of the viable tumor nuclei.||||||F|||20101214105651OBX|50|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|51|TX|4788372^CONSULT REPORT^L01N||      TTF1 positivity is not specific; Although a lung primary cannot be excluded, up to 50% of||||||F|||20101214105651OBX|52|TX|4788372^CONSULT REPORT^L01N||      high grade neuroendocrine carcinomas from sites other than the lung, may show TTF1||||||F|||20101214105651OBX|53|TX|4788372^CONSULT REPORT^L01N||      positivity.  I also did CDX2 immunostains which show patchy positivity further raising||||||F|||20101214105651OBX|54|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|55|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|56|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|57|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|58|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|59|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|60|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|61|TX|4788372^CONSULT REPORT^L01N||      the suspicion of a possible gastrointestinal origin, although serotonin immunostains are||||||F|||20101214105651OBX|62|TX|4788372^CONSULT REPORT^L01N||      negative.||||||F|||20101214105651OBX|63|TX|4788372^CONSULT REPORT^L01N||||||||F|||20101214105651OBX|64|TX|4788372^CONSULT REPORT^L01N||      In summary, the sample is limited, but the tumor that is viable has the morphology and||||||F|||20101214105651OBX|65|TX|4788372^CONSULT REPORT^L01N||      immunostaining pattern of a high grade neuroendocrine carcinoma (high mitotic activity,||||||F|||20101214105651OBX|66|TX|4788372^CONSULT REPORT^L01N||      Ki67 index of 50%). No other carcinoma component is present.  As originally reported, it||||||F|||20101214105651OBX|67|TX|4788372^CONSULT REPORT^L01N||      is difficult to determine site of origin in this small biopsy fragment.  A pancreatic||||||F|||20101214105651OBX|68|TX|4788372^CONSULT REPORT^L01N||      origin is a possibility, but a primary in other areas of the gastrointestinal tract||||||F|||20101214105651OBX|69|TX|4788372^CONSULT REPORT^L01N||      (including gallbladder), lung, or other organs with metastasis to the upper abdomen||||||F|||20101214105651OBX|70|TX|4788372^CONSULT REPORT^L01N||      (liver, gallbladder) cannot be excluded.||||||F|||20101214105651
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214110750||ORU^R01|Q199823648T198320720|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452258^101AP|4388088^CONSULT REPORT^L01N|||20101214105300|||||||20101214105300|^^Outside Block/Slide|1000000^Unknown1, Physician, MD||||RF-10-0000900||20101214110752||AP|F||1^^^20101214105300^^~^^^^^RT|1001745^Test, Physician - p-Test PhysicianOBX|1|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||*****Consultation Addendum Report*****||||||F|||20101214110752OBX|2|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|3|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Accession Number     RF-10-0000900||||||F|||20101214110752OBX|4|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 10:53 MST||||||F|||20101214110752OBX|5|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 10:53 MST||||||F|||20101214110752OBX|6|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214110752OBX|7|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|8|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|9|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Consult Addendum Diagnosis||||||F|||20101214110752OBX|10|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Slides and blocks reviewed by Lung specialty group.  Diagnosis remains unchanged.||||||F|||20101214110752OBX|11|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|12|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214110752OBX|13|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|14|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214110752OBX|15|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Verified: 2010/12/14 11:07 AM||||||F|||20101214110752OBX|16|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214110752OBX|17|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|18|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214110752OBX|19|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      ________||||||F|||20101214110752OBX|20|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|21|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|22|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Consult Addendum Discussion||||||F|||20101214110752OBX|23|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      No discussion.||||||F|||20101214110752OBX|24|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|25|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|26|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      *****Consultation Report*****||||||F|||20101214110752OBX|27|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|28|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Accession Number     RF-10-0000900||||||F|||20101214110752OBX|29|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 10:53 MST||||||F|||20101214110752OBX|30|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 10:53 MST||||||F|||20101214110752OBX|31|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214110752OBX|32|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|33|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|34|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Consult Description||||||F|||20101214110752OBX|35|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Consult Specimen||||||F|||20101214110752OBX|36|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|37|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Consult Type: TBCC Consult||||||F|||20101214110752OBX|38|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Materials received:  21 Block  45 Slides||||||F|||20101214110752OBX|39|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Received from:  PLC  Received by:  CG||||||F|||20101214110752OBX|40|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|41|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|42|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Diagnosis||||||F|||20101214110752OBX|43|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Abdominal Midline Mass, Core Biopsies:||||||F|||20101214110752OBX|44|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||            -     High grade neuroendocrine carcinoma||||||F|||20101214110752OBX|45|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||            -     (Extensive necrosis, prominent mitotic activity, Ki67 index greater||||||F|||20101214110752OBX|46|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||                  than 50%)||||||F|||20101214110752OBX|47|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|48|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|49|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|50|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|51|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|52|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|53|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|54|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|55|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||            -     Site of primary origin cannot be determined on histology (see micro||||||F|||20101214110752OBX|56|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|57|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214110752OBX|58|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|59|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214110752OBX|60|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Verified: 2010/12/14 10:56 AM||||||F|||20101214110752OBX|61|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214110752OBX|62|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|63|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214110752OBX|64|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      ________||||||F|||20101214110752OBX|65|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|66|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|67|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Microscopic Description||||||F|||20101214110752OBX|68|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      This case was reviewed at the request of Dr. M. V, GI Oncology Group at the Tom Baker||||||F|||20101214110752OBX|69|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Cancer Centre.  This patient has a midline upper abdominal mass which clinically would be||||||F|||20101214110752OBX|70|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      most consistent with a gallbladder carcinoma. Specific question in this review is whether||||||F|||20101214110752OBX|71|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      the possibility of a pancreatic primary as suggested originally, or other site of primary||||||F|||20101214110752OBX|72|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      is more likely.||||||F|||20101214110752OBX|73|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|74|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      This biopsy specimen consisted of two cores of tissue that consist of fibrous tissue and||||||F|||20101214110752OBX|75|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      necrotic areas with only small foci of residual viable neoplastic epithelium.  This||||||F|||20101214110752OBX|76|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      appears to be arranged into vague nests focally showing small intercellular lumina. There||||||F|||20101214110752OBX|77|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      appears to be a peripheral arrangement of nuclei and many of the nuclei have a granular||||||F|||20101214110752OBX|78|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      chromatin in a pattern raising the possibility of neuroendocrine tumor.  However, there||||||F|||20101214110752OBX|79|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      is prominent mitotic activity (three or more per high power field on the limited||||||F|||20101214110752OBX|80|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      material) and moderate nuclear pleomorphism. A positive synaptophysin immunostain||||||F|||20101214110752OBX|81|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      supports neuroendocrine differentiation.  I have also done a Ki67 which shows nuclear||||||F|||20101214110752OBX|82|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      positivity in approximately 50% of the viable tumor nuclei.||||||F|||20101214110752OBX|83|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|84|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      TTF1 positivity is not specific; Although a lung primary cannot be excluded, up to 50% of||||||F|||20101214110752OBX|85|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      high grade neuroendocrine carcinomas from sites other than the lung, may show TTF1||||||F|||20101214110752OBX|86|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      positivity.  I also did CDX2 immunostains which show patchy positivity further raising||||||F|||20101214110752OBX|87|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      the suspicion of a possible gastrointestinal origin, although serotonin immunostains are||||||F|||20101214110752OBX|88|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      negative.||||||F|||20101214110752OBX|89|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||||||||F|||20101214110752OBX|90|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      In summary, the sample is limited, but the tumor that is viable has the morphology and||||||F|||20101214110752OBX|91|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      immunostaining pattern of a high grade neuroendocrine carcinoma (high mitotic activity,||||||F|||20101214110752OBX|92|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      Ki67 index of 50%). No other carcinoma component is present.  As originally reported, it||||||F|||20101214110752OBX|93|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      is difficult to determine site of origin in this small biopsy fragment.  A pancreatic||||||F|||20101214110752OBX|94|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      origin is a possibility, but a primary in other areas of the gastrointestinal tract||||||F|||20101214110752OBX|95|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      (including gallbladder), lung, or other organs with metastasis to the upper abdomen||||||F|||20101214110752OBX|96|TX|4788369^CONSULTATION ADDENDUM REPORT^L01N||      (liver, gallbladder) cannot be excluded.||||||F|||20101214110752
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20101214111339||ORU^R01|Q199823654T198320726|P|2.3PID|1|798274114^^^AB|2250008675^^^80016||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|A|61^636^2^80016|||||||||||||||AOBR|1||0176452202^101AP|313046^SURGICAL PATHOLOGY REPORT^L01N|||20101214102300|||||||20101214102300|^^LN, Regional Resection(5)|1001745^Test, Physician - p-Test Physician||||SF-10-0020326||20101214111336||AP|F||1^^^20101214102300^^~^^^^^RT|OBX|1|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||*****Consultative Addendum Report*****||||||F|||20101214111336OBX|2|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|3|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Accession Number     SF-10-0020326||||||F|||20101214111336OBX|4|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 10:23 MST||||||F|||20101214111336OBX|5|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 10:23 MST||||||F|||20101214111336OBX|6|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214111336OBX|7|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|8|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|9|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Consultative Add Reason||||||F|||20101214111336OBX|10|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Addendum to report outside consult.||||||F|||20101214111336OBX|11|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|12|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|13|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Addendum Diagnosis||||||F|||20101214111336OBX|14|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Case sent to Mayo Clinic for consultation and they agree with original diagnosis.||||||F|||20101214111336OBX|15|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|16|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214111336OBX|17|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|18|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214111336OBX|19|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Verified: 2010/12/14 11:13 AM||||||F|||20101214111336OBX|20|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214111336OBX|21|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|22|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214111336OBX|23|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      ________||||||F|||20101214111336OBX|24|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|25|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|26|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Addendum Discussion||||||F|||20101214111336OBX|27|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Testing Netcare and POS addendums.||||||F|||20101214111336OBX|28|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|29|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|30|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      *****Surgical Pathology Report*****||||||F|||20101214111336OBX|31|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|32|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Accession Number     SF-10-0020326||||||F|||20101214111336OBX|33|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Collected Date/Time  2010-12-14 10:23 MST||||||F|||20101214111336OBX|34|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Received Date/Time   2010-12-14 10:23 MST||||||F|||20101214111336OBX|35|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Pathologist          Gates, Colleen||||||F|||20101214111336OBX|36|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|37|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|38|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Specimen Description||||||F|||20101214111336OBX|39|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      A.  Inferior pulmonary ligament node||||||F|||20101214111336OBX|40|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B.  Right lower lobe superior segment||||||F|||20101214111336OBX|41|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      C.  Right middle lobe wedge resection||||||F|||20101214111336OBX|42|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      D.  #10R lymph node||||||F|||20101214111336OBX|43|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      E.  Subcarinal #7 lymph node||||||F|||20101214111336OBX|44|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      F.  #12 right upper lobe node||||||F|||20101214111336OBX|45|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G.  Right upper lobe posterior segment *please note 2 nodules*||||||F|||20101214111336OBX|46|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|47|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|48|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Clinical Information||||||F|||20101214111336OBX|49|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Smoker, enlarging RUL nodule, incidental RML nodule - query metastatic lung Ca.||||||F|||20101214111336OBX|50|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|51|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214111336OBX|52|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      __||||||F|||20101214111336OBX|53|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|54|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|55|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|56|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|57|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|58|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|59|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|60|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Diagnosis||||||F|||20101214111336OBX|61|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      A.  Inferior Pulmonary Ligament Node:||||||F|||20101214111336OBX|62|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214111336OBX|63|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|64|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B.  Right Lower Lobe Superior Segment:||||||F|||20101214111336OBX|65|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Moderately differentiated adenocarcinoma (1.4 cm),with areas of||||||F|||20101214111336OBX|66|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  bronchiolo-alveolar carcinoma like growth pattern.||||||F|||20101214111336OBX|67|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Arises in a background of respiratory bronchiolitis, congestion and||||||F|||20101214111336OBX|68|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                   mild emphysematous change.||||||F|||20101214111336OBX|69|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Resection margins negative for malignancy and dysplasia||||||F|||20101214111336OBX|70|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Pleura free of tumor.||||||F|||20101214111336OBX|71|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|72|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      C.  Right Middle Lobe Wedge Resection:||||||F|||20101214111336OBX|73|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Hyalinized fibrous nodule with chronic inflammatory cells.||||||F|||20101214111336OBX|74|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Negative for Malignancy and Dysplasia.||||||F|||20101214111336OBX|75|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|76|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      D.  #10 R Lymph Node:||||||F|||20101214111336OBX|77|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214111336OBX|78|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|79|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      E.  Subcarinal #7 Lymph Node:||||||F|||20101214111336OBX|80|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214111336OBX|81|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|82|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      F.  #12 Right Upper Lobe Node:||||||F|||20101214111336OBX|83|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     Negative for malignancy.||||||F|||20101214111336OBX|84|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|85|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G.  Right Upper Lobe, Posterior Segment:||||||F|||20101214111336OBX|86|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            -     1)Moderately differentiated adenocarcinoma (1.7 cm) in a||||||F|||20101214111336OBX|87|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  background of respiratory bronchiolitis and emphysematous change||||||F|||20101214111336OBX|88|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|89|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Tumor is morphologically different than that in specimen B and thus||||||F|||20101214111336OBX|90|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  is reflective of a second primary site.||||||F|||20101214111336OBX|91|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|92|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  2)Moderately differentiated adenocarcinoma (2.0 cm),with areas of||||||F|||20101214111336OBX|93|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  bronchiolo-alveolar carcinoma like growth pattern.||||||F|||20101214111336OBX|94|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Arises in a background of respiratory bronchiolitis, congestion and||||||F|||20101214111336OBX|95|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                   mild emphysematous change.||||||F|||20101214111336OBX|96|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|97|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  Tumor is morphologically the same as that seen in specimen B but||||||F|||20101214111336OBX|98|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  different from the first tumor in specimen G. Thus reflective of||||||F|||20101214111336OBX|99|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  pulmonary metastases.||||||F|||20101214111336OBX|100|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|101|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  3) One microscopic area of Bronchioalveolar Carcinoma (0.6 cm)||||||F|||20101214111336OBX|102|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|103|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  4)  Atypical adenomatous hyperplasia (AAH)||||||F|||20101214111336OBX|104|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|105|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                  5) Resection margins negative for malignancy and dysplasia||||||F|||20101214111336OBX|106|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|107|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|108|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|109|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|110|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|111|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|112|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|113|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|114|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||                      Pleura free of tumor.||||||F|||20101214111336OBX|115|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|116|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Reported by: Gates, C.||||||F|||20101214111336OBX|117|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|118|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Electronically signed by: Gates, Colleen||||||F|||20101214111336OBX|119|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Verified: 2010/12/14 10:40 AM||||||F|||20101214111336OBX|120|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      CG/CG||||||F|||20101214111336OBX|121|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|122|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      _________________________________________________________________________________________||||||F|||20101214111336OBX|123|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      ________||||||F|||20101214111336OBX|124|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|125|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|126|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Synoptic Report||||||F|||20101214111336OBX|127|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G: CLS Lung Resection||||||F|||20101214111336OBX|128|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Specimen Type:||||||F|||20101214111336OBX|129|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Wedge resection||||||F|||20101214111336OBX|130|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Laterality:||||||F|||20101214111336OBX|131|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Right||||||F|||20101214111336OBX|132|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor Site:||||||F|||20101214111336OBX|133|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Upper lobe||||||F|||20101214111336OBX|134|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor type:||||||F|||20101214111336OBX|135|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Adenocarcinoma||||||F|||20101214111336OBX|136|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Grade:||||||F|||20101214111336OBX|137|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Moderately differentiated||||||F|||20101214111336OBX|138|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Location:||||||F|||20101214111336OBX|139|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Peripheral||||||F|||20101214111336OBX|140|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Satellite nodules in same lobe:||||||F|||20101214111336OBX|141|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Positive||||||F|||20101214111336OBX|142|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Intrapulmonary metastases:||||||F|||20101214111336OBX|143|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Positive||||||F|||20101214111336OBX|144|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Vascular invasion:||||||F|||20101214111336OBX|145|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|146|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Perineural invasion:||||||F|||20101214111336OBX|147|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|148|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Margins: - Bronchial:||||||F|||20101214111336OBX|149|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor 0.5 cm away from stapled resection margin||||||F|||20101214111336OBX|150|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Margins: - Medistinal:||||||F|||20101214111336OBX|151|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|152|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Pleural invasion:||||||F|||20101214111336OBX|153|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|154|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Atelectasis/Obstructive Pneumonia:||||||F|||20101214111336OBX|155|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|156|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Lymph nodes||||||F|||20101214111336OBX|157|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|158|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B: CLS Lung Resection||||||F|||20101214111336OBX|159|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Specimen Type:||||||F|||20101214111336OBX|160|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Wedge resection||||||F|||20101214111336OBX|161|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Laterality:||||||F|||20101214111336OBX|162|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Right||||||F|||20101214111336OBX|163|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor Site:||||||F|||20101214111336OBX|164|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Lower lobe||||||F|||20101214111336OBX|165|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor type:||||||F|||20101214111336OBX|166|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Adenocarcinoma||||||F|||20101214111336OBX|167|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Grade:||||||F|||20101214111336OBX|168|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Moderately differentiated||||||F|||20101214111336OBX|169|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|170|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|171|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|172|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|173|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|174|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|175|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Location:||||||F|||20101214111336OBX|176|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Peripheral||||||F|||20101214111336OBX|177|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Size:||||||F|||20101214111336OBX|178|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Maximum dimension  1.4  cm||||||F|||20101214111336OBX|179|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Satellite nodules in same lobe:||||||F|||20101214111336OBX|180|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|181|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Vascular invasion:||||||F|||20101214111336OBX|182|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|183|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Perineural invasion:||||||F|||20101214111336OBX|184|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|185|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Margins: - Bronchial:||||||F|||20101214111336OBX|186|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Tumor 1.5 cm away from stapled resection margin||||||F|||20101214111336OBX|187|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Pleural invasion:||||||F|||20101214111336OBX|188|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|189|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Atelectasis/Obstructive Pneumonia:||||||F|||20101214111336OBX|190|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|191|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      In situ component:||||||F|||20101214111336OBX|192|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|193|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Lymph nodes:||||||F|||20101214111336OBX|194|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Negative||||||F|||20101214111336OBX|195|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|196|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|197|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Gross Description||||||F|||20101214111336OBX|198|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Received are specimens A to G.  All requisitions and specimen containers are labelled||||||F|||20101214111336OBX|199|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      with the patient's name.  The cassettes and AP identifiers are labelled with the Surgical||||||F|||20101214111336OBX|200|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Number SF10-19864.||||||F|||20101214111336OBX|201|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|202|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      A.  Received is a single grey/tan irregular soft tissue nodule measuring 1.0 x 0.8 x 0.2||||||F|||20101214111336OBX|203|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      cm.  It is trisected and submitted in one block.  ARH/ct||||||F|||20101214111336OBX|204|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|205|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B.  The specimen consists of a lung wedge (10 x 6 x 2.5 cm) with a single yellow||||||F|||20101214111336OBX|206|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      spiculated nodule (1.0 cm) located 1.5 cm from the painted (black) staple margin.||||||F|||20101214111336OBX|207|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Representative section submitted for QS.  IC/ct||||||F|||20101214111336OBX|208|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|209|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Another stapled margin is identified opposite to the first.  The staples are cut and the||||||F|||20101214111336OBX|210|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      resection surface is painted blue.  The lung wedge is sectioned serially. The primary||||||F|||20101214111336OBX|211|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      tumor mass identified during the frozen section is seen.  No other tumor masses, areas of||||||F|||20101214111336OBX|212|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      consolidation or fibrosis are identified.  Sections are submitted as follows:||||||F|||20101214111336OBX|213|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|214|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B2-B3 sections of the primary tumor mass, submitted in toto||||||F|||20101214111336OBX|215|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B4-B6 representative sections of the lung parenchyma adjacent to the tumor mass||||||F|||20101214111336OBX|216|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B7-B10 random representative sections of the grossly normal-appearing lung parenchyma||||||F|||20101214111336OBX|217|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      ARH/ct||||||F|||20101214111336OBX|218|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|219|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      C.  The specimen consists of a lung wedge (3.5 x 2.5 x 0.5 cm) containing a single||||||F|||20101214111336OBX|220|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      subpleural nodule (0.1 cm and ? circled).  Staple resection margin painted black.  Nodule||||||F|||20101214111336OBX|221|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      submitted in toto for QS.  IC/ct||||||F|||20101214111336OBX|222|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|223|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      The remaining portion of the wedge was sectioned serially and appears to be grossly||||||F|||20101214111336OBX|224|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      normal.  Random representative sections will be submitted in blocks C2-C4.  ARH/ct||||||F|||20101214111336OBX|225|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|226|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      D.  Received is a single grey/tan irregular portion of soft tissue measuring 1.5 x 0.6 x||||||F|||20101214111336OBX|227|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      0.2 cm.  It is bisected longitudinally and submitted totally in one block.||||||F|||20101214111336OBX|228|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|229|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|230|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|231|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|232|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|233|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|234|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|235|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|236|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      E.  Received are two portions of irregular grey/tan tissue measuring in aggregate 1.2 x||||||F|||20101214111336OBX|237|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      0.8 x 0.3 cm.  Each of the portions are bisected longitudinally and submitted totally in||||||F|||20101214111336OBX|238|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      blocks E1 and E2.||||||F|||20101214111336OBX|239|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|240|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      F.  Received are multiple portions of grey/tan and irregular soft tissue measuring in||||||F|||20101214111336OBX|241|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      aggregate 1.5 x 1.3 x 0.2 cm.  The largest portion is bisected and submitted totally in||||||F|||20101214111336OBX|242|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      block F1.  The remaining portions are submitted totally in block F2.||||||F|||20101214111336OBX|243|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|244|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G.  Received is a wedge of lung tissue measuring 13.0 x 7.5 x 1.3 cm.  A stapled||||||F|||20101214111336OBX|245|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      resection margin is identified.  The stapled resection margin is painted blue.  The||||||F|||20101214111336OBX|246|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      pleural surface shows puckering, at a distance of 2.5 cm from the stapled margin.||||||F|||20101214111336OBX|247|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Underneath this puckered pleural surface, an irregular firm-to-hard nodule can be||||||F|||20101214111336OBX|248|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      palpated.  On serial sectioning of the lung wedge, a yellow/tan firm-to-hard irregular||||||F|||20101214111336OBX|249|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      nodule is identified coming within 0.2 cm of the pleural surface and 0.5 cm from the||||||F|||20101214111336OBX|250|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      stapled resection margin.  The mass itself measures 1.7 x 1.1 x 1.2 cm.  Another||||||F|||20101214111336OBX|251|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      irregular firm-to-hard yellow/tan mass is identified coming within 0.2 cm of the puckered||||||F|||20101214111336OBX|252|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      pleural surface.  This mass measures 2.0 x 1.1 x 1.1 cm.  This mass is located at a||||||F|||20101214111336OBX|253|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      distance of 1.7 cm from the first tumor mass (where the depth of the lung wedge is 4.5||||||F|||20101214111336OBX|254|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      cm).  The rest of the lung parenchyma appears to be grossly normal with no areas of||||||F|||20101214111336OBX|255|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      fibrosis or consolidation identified.  Sections are submitted as follows:||||||F|||20101214111336OBX|256|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|257|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G1-G3 sections of the primary tumor mass, submitted in toto||||||F|||20101214111336OBX|258|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G4 sections of the primary and secondary tumor mass to show the relationship between the||||||F|||20101214111336OBX|259|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      two (contiguous sections)||||||F|||20101214111336OBX|260|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G5-G7 representative sections of the secondary tumor mass to show its relationship with||||||F|||20101214111336OBX|261|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      puckered pleural surface||||||F|||20101214111336OBX|262|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      G8-G12 random representative sections of the grossly normal-appearing lung parenchyma||||||F|||20101214111336OBX|263|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      ARH/ct||||||F|||20101214111336OBX|264|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|265|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|266|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Frozen Section Diagnosis||||||F|||20101214111336OBX|267|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      B.  Right Lower Lobe Superior Segment:||||||F|||20101214111336OBX|268|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            - Well-differentiated adenocarcinoma with BAC features  /IC  Conf #65||||||F|||20101214111336OBX|269|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|270|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      C.  Right Middle Lobe Wedge:||||||F|||20101214111336OBX|271|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||            - Benign fibrous nodule, negative for malignancy  IC/ct  Conf #66||||||F|||20101214111336OBX|272|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|273|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Reported by: V V Falck||||||F|||20101214111336OBX|274|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|275|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||||||||F|||20101214111336OBX|276|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Pathologist Comment||||||F|||20101214111336OBX|277|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      Sections show insitu and invasive adenocarcinomas. One of the adenocarcinomas is distinct||||||F|||20101214111336OBX|278|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      from the rest and thus indicative of multiple primary tumors, however the remaining||||||F|||20101214111336OBX|279|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      tumors in the two separate lobes are histologically similar and consistent with pulmonary||||||F|||20101214111336OBX|280|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      metastases. As the lower lobe tumor is smaller than the upper lobe tumor and insitu||||||F|||20101214111336OBX|281|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      disease is noted in the upper lobe, the upper lobe would be regarded as the primary tumor||||||F|||20101214111336OBX|282|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      in this case. This means two separate primary tumors are present in the upper lobe with||||||F|||20101214111336OBX|283|TX|5925225^CONSULTATIVE ADDENDUM REPORT^L01N||      upper lobe and lower lobe metastases from one of the two primary tumors.||||||F|||20101214111336
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110105150337||ORU^R01|Q199836608T198333711|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439032^101LA|2921248^SODIUM^L01N|||20101203111100|||||||20101203111100|^^|1001745^Test, Physician - p-Test Physician||||10-337-300034||20101203114337||LA|F||1^^^20101203111100^^RT~^^^^^RT|NTE|1|C|patient is feeling blue todayNTE|2|C|But it is fridayOBX|1|NM|4673500^SODIUM^L01N||135|mmol/L|133-145||||C|||20101203114908NTE|1||Corrected from 140 mmol/L on 12/03/10 11:49:08 MST by CDREWS02.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110105150927||ORU^R01|Q199836610T198333713|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176439032^101LA|2921248^SODIUM^L01N|||20101203111100|||||||20101203111100|^^|1001745^Test, Physician - p-Test Physician||||10-337-300034||20101203114337||LA|F||1^^^20101203111100^^RT~^^^^^RT|NTE|1|C|patient is feeling blue todayNTE|2|C|But it is fridayOBX|1|NM|4673500^SODIUM^L01N||135|mmol/L|133-145||||C|||20110105150922NTE|1|C|patient is red todayNTE|2||Corrected from 135 mmol/L on 01/05/11 15:09:22 MST by DATKINSON03.NTE|3||Corrected from 140 mmol/L on 12/03/10 11:49:08 MST by CDREWS02.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110107124858||ORU^R01|Q199837792T198334885|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176479899^101LA|4387636^LIPID PANEL^L01N|||20110107124300|||||||20110107124400|^^|1001745^Test, Physician - p-Test Physician||||11-007-300003||20110107124855||LA|F||1^^^20110107124300^^RT~^^^^^RT|OBX|1|NM|4673389^CHOLESTEROL^L01N||5.00|mmol/L|3.80-5.20||||F|||20110107124852OBX|2|NM|4673578^TRIGLYCERIDES^L01N||5.00|mmol/L|0.60-2.30|H|||F|||20110107124852OBX|3|NM|4673719^HDL CHOLESTEROL^L01N||1.00|mmol/L|>=0.91||||F|||20110107124852OBX|4|NM|4671640^TOTAL: HDL CHOLESTEROL RATIO^L01N||1.0||||||F|||20110107124852NTE|1|I|10-YR Risk Of CAD (Death or Non-fatal MI) and Target Lipid ValuesNTE|2|I|RISK LEVEL                                                   TARGETS: LDL-CNTE|3|I|TC/HDL-CNTE|4|I|High (>= 20%): or  Diabetes, or CAD/PAD/                       < 2.0    andNTE|5|I|< 4.0NTE|6|I|     CVD/CRFNTE|7|I|Moderate  (10-19%)NTE|8|I|< 3.5    or         < 5.0NTE|9|I|Low     (< 10%)NTE|10|I|< 5.0    or         < 6.0NTE|11|I|GUIDELINE: CAN J CARDIOL 2006;  22:  913-927OBX|5|NM|4671331^LDL, CALCULATED^L01N||5.00|mmol/L|2.00-3.40|H|||F|||20110107124852OBX|6|ST|6188004^HOURS  FASTING^L01N||10 hours||||||F|||20110107124852
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110107125544||ORU^R01|Q199837806T198334898|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176479912^101LA|2921814^TROPONIN T^L01N|||20110107124300|||||||20110107124400|^^|1001745^Test, Physician - p-Test Physician||||11-007-300003||20110107125543||LA|F||1^^^20110107124300^^RT~^^^^^RT|OBX|1|NM|4674004^TROPONIN T^L01N||10.00|ug/L|0.00-0.02|C|||F|||20110107125540
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110107143252||ORU^R01|Q199838016T198335107|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176480449^101LA|5879562^TROPONIN I (VIDAS)^L01N|||20110107142300|||||||20110107143100|^^|1001745^Test, Physician - p-Test Physician||||11-007-300015||20110107143252||LA|F||1^^^20110107142300^^ST~^^^^^ST|OBX|1|NM|4674001^TROPONIN I (VIDAS)^L01N||0.06|ug/L|<=0.01|H|||F|||20110107143248NTE|1|C|Troponin I value is inconclusive for acute MI and may be due to myocardialNTE|2|C|injury.  Repeat ordering may be warranted in some clinical situations.
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110112095002||ORU^R01|Q199839856T198336943|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176485077^101LA|4655308^GLUCOSE TOLERANCE PREG^L01N|||20110112070000|||||||20110112094900|^^|1001745^Test, Physician - p-Test Physician||||11-012-300002||20110112094957||LA|F||1^^^20110112070000^^TM~^^^20110112070000^^RT|OBX|1|NM|6188134^GLUCOSE TOLERANCE FASTING.^L01N||4.8|mmol/L|||||F|||20110112094955NTE|1|I|Interpretive criteria:NTE|2|I|Fasting     1 Hr      2 HrNTE|3|I|5.3            10.6      8.9 mmol/LNTE|4|I|If one of three values is met or exceeded, the diagnosis is impaired glucose tolerance of pregnancy.  If two or three values are met or exceeded, the diagnosis of gestational diabetes mellitus has been established. Please see Canadian Diabetes Association 2008 practice guidelines.OBX|2|NM|6187984^GLUCOSE DOSAGE.(G)^L01N||100|g|||||F|||20110112094955OBX|3|TX|6187989^HOURS FASTING.^L01N||10 hours||||||F|||20110112094955OBX|4|NM|6388149^WEEKS GESTATION.^L01N||28|week(s)|||||F|||20110112094955
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110112095019||ORU^R01|Q199839858T198336945|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176485077^101LA|4655308^GLUCOSE TOLERANCE PREG^L01N|||20110112080000|||||||20110112094900|^^|1001745^Test, Physician - p-Test Physician||||11-012-300003||20110112095016||LA|F||1^^^20110112080000^^TM~^^^20110112070000^^RT|OBX|1|NM|6188134^GLUCOSE TOLERANCE FASTING.^L01N||4.8|mmol/L|||||F|||20110112094955NTE|1|I|Interpretive criteria:NTE|2|I|Fasting     1 Hr      2 HrNTE|3|I|5.3            10.6      8.9 mmol/LNTE|4|I|If one of three values is met or exceeded, the diagnosis is impaired glucose tolerance of pregnancy.  If two or three values are met or exceeded, the diagnosis of gestational diabetes mellitus has been established. Please see Canadian Diabetes Association 2008 practice guidelines.OBX|2|NM|6187984^GLUCOSE DOSAGE.(G)^L01N||100|g|||||F|||20110112094955OBX|3|TX|6187989^HOURS FASTING.^L01N||10 hours||||||F|||20110112094955OBX|4|NM|6388149^WEEKS GESTATION.^L01N||28|week(s)|||||F|||20110112094955OBX|5|NM|4673668^GLUCOSE TOLERANCE 1.0H.^L01N||5.2|mmol/L|||||F|||20110112095015
MSH|^~\&|OPEN ENGINE|CLS|Egate|POSP|20110112095039||ORU^R01|Q199839860T198336947|P|2.3PID|1|798274114^^^AB|2250008675^^^88000||MillMCK CB FSI, Karla||19701027|F||||83||PV1|1|E|05031^^^88000|||||||||||||||EOBR|1||0176485077^101LA|4655308^GLUCOSE TOLERANCE PREG^L01N|||20110112090000|||||||20110112094900|^^|1001745^Test, Physician - p-Test Physician||||11-012-300004||20110112095036||LA|F||1^^^20110112090000^^TM~^^^20110112070000^^RT|OBX|1|NM|6188134^GLUCOSE TOLERANCE FASTING.^L01N||4.8|mmol/L|||||F|||20110112094955NTE|1|I|Interpretive criteria:NTE|2|I|Fasting     1 Hr      2 HrNTE|3|I|5.3            10.6      8.9 mmol/LNTE|4|I|If one of three values is met or exceeded, the diagnosis is impaired glucose tolerance of pregnancy.  If two or three values are met or exceeded, the diagnosis of gestational diabetes mellitus has been established. Please see Canadian Diabetes Association 2008 practice guidelines.OBX|2|NM|6187984^GLUCOSE DOSAGE.(G)^L01N||100|g|||||F|||20110112094955OBX|3|TX|6187989^HOURS FASTING.^L01N||10 hours||||||F|||20110112094955OBX|4|NM|6388149^WEEKS GESTATION.^L01N||28|week(s)|||||F|||20110112094955OBX|5|NM|4673668^GLUCOSE TOLERANCE 1.0H.^L01N||5.2|mmol/L|||||F|||20110112095015OBX|6|NM|4676143^GLUCOSE TOLERANCE 2.0H.^L01N||5.9|mmol/L|||||F|||20110112095035
